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Hepatitis C virus (HCV) is an important human pathogen that causes chronic 
hepatitis cirrhosis, steatosis and hepatocellular carcinoma (HCC) worldwide.  Although 
current FDA-approved drugs are partially effective in the treatment of HCV, methods for 
cure and vaccine against the virus are still awaited.  My thesis work presented here is 
focused on finding mechanism (s) of HCV-induced hepatocarcinogenesis and devising 
novel means to combat the HCV infection.  
 
Herein, we have shown that long-term HCV expression results in the acquisition 
of cancer stem-like cells (CSCs) traits in liver derived cell lines. These traits include 
enhanced expression of putative stem cell markers DCAMKL-1, Lgr5, CD133 and c-
Myc. We also showed that HCV replication is severely impaired by siRNA-led depletion 
of the microtubule filaments (MTFs)-associated DCAMKL-1. The cholesterol-lowering 
drug, fluvastatin, reduces DCAMKL-1 RNA and affects its protein localization on the 
microtubule filaments resulting in marked reduction in the viral RNA and protein 
abundance. The mouse xenografts, liver biopsy and tissue microarrays unveiled 
overexpression of DCAMKL-1 during chronic HCV infection and cirrhosis, and in the 
HCV-replicon expressing cells.  We further demonstrate that HCV results in excessive 
expression of a-fetoprotein, cytokeratin-19, c-Myc, and c-Src, and activation of b-catenin 
pathway in the absence of Wnt ligand.  The result presented here implicates a novel 
 iii 
cellular internal ribosome entry site (IRES) element in the c-Src mRNA responsible for 
the overexpression of c-Src proto-oncogene under stressed conditions such as HCV 
infection.  
 
These results presented here collectively suggest that HCV exhibits ability to 
induce reprogramming and/or retrodifferentiation of the host cells and further revealed a 
novel HCV-(DCAMKL-1)-MTF-CSCs axis that might be responsible for the HCV RNA 
abundance in the infected cells and HCV-induced hepatocarcinogenesis. The putative 
stem cell marker, DCAMKL-1, represents a novel cellular target for combating HCV and 
liver cancer. The concept of a ‘virus-induced stem cell traits’ can also be extrapolated to 
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Chapter One: Hepatitis C Virus (HCV): a silent epidemic 
 
1. My exploration in the world of tiny microbes 
Viruses are fascinating organic macromolecular complexes that exist as obligate 
parasites and exhibit high degree of adaptability in their hosts. Although these infectious 
agents have caused enormous loss to humans and non-humans equally for centuries, they 
also have taught us about the secrets of life, death and diseases. In fact, the viruses have 
shaped various life forms on our planet by shuffling and redistributing genes among 
organisms.  Relatively easy manipulation of their genome offers opportunity for the 
investigators to engineer novel means for combating multitude of diseases including 
cancer.  
 
Hepatitis C virus (HCV) is one of the highly ‘evolved’ viruses that have clearly 
challenged modern human intelligence by posing major health problems worldwide 
including my country (Egypt) in terms of both mortality and morbidity.  Recent estimates 
have shown astounding healthcare spending in USA; rising from $627 million to $6.9 
billion (a 10-fold increase) for HCV monoinfection and $63 million to $655 million for 
HCV-HIV co-infection during last decade. These reasons made me to believe that my 
medical background combined with extensive research may contribute to alleviate human 
sufferings due to HCV infection. In this quest, I joined Dr. Naushad Ali’s laboratory who 
had published numerous papers on molecular mechanism of translation and replication of 
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HCV. Here, I began working on how HCV survives in human liver for decades without 
integrating into the host genome, and how its long-term persistence induces cirrhosis and 
liver cancer (hepatocellular carcinoma). To begin with, I will put my efforts in this 
chapter to update existing knowledge on the HCV life-cycle, and the advances made in 
the field of diagnosis, prevention and treatment for hepatitis C.  The next 3 chapters 
(Chapters 2-4) are dedicated to describe my research efforts, important findings during  
my thesis work, and their implications in designing new treatment strategies against HCV 
and liver cancer.  
 
2. Historical Perspective of Hepatitis  
 
 In the late 1960's, two hepatitis viruses, hepatitis A virus (HAV) and hepatitis B 
virus (HBV) that caused infectious jaundice, were known and were distinguished on the 
basis of transmission route and reactivity of patient’s serum to their respective antigens 
(Fig 1a).   During early 1970's, transfusion recipients were being screened with the 
concept that hepatitis B would be the culprit for transfusion-associated hepatitis, but 
neither hepatitis A nor B viruses were found to be responsible.  Another hepatitis agent, 
hepatitis D virus (HDV) was although identified, it was found to be a defective virus that 
is always associated and dependent on HBV infection (Manns 2000).  
 Extensive epidemiological studies from around the world found a history of 
chronic HBV persistence (over 6 months) in 5% of the infected individual.  Intriguingly, 
over 50% patients with blood transfusion-associated hepatitis exhibited chronic diseases.            
 These observations led to the search for non-A non-B hepatitis agent in these cases. 
Using molecular biological approach during late 1989, a new RNA virus, named hepatitis 
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C virus (HCV) was discovered at Chiron Corporation (USA) as a causative agent for the 
parentrally transmitted NANB hepatitis cases (Choo et al 1992). With the development of 
RT-PCR and ELISA tests, it was quickly apparent that over 80% of HCV infected 
individuals develop chronic hepatitis(Guobuzaite et al 2008).  Follow-up over 20 years 
and perspective studies showed that many infected persons developed progressive liver 
fibrosis, often extending to cirrhosis and/or liver cancer. The long-term studies on natural 
history has been proven to be challenging as the disease onset is often subclinical and 
progression is extremely slow (Farci et al 1991).  Due to these reasons, hepatitis C is also 
termed as a ’silent killer’ diseases. 
 
The enterically transmitted NANB hepatitis was later found to be caused by a 
calicivirus-like agent termed hepatitis E virus (HEV).  Similar to HAV, HEV usually 
causes self-limiting acute hepatitis during sporadic infection or outbreaks in the 
developing countries. However, higher mortality rate (~20%) among HEV patients due to 
fulminant hepatitis has been reported for pregnant women than other hepatitis viruses 
(Jilani et al 2007) . Recent studies also indicate that HEV exposure to pregnant women is 
extremely high (85%) in the Nile Delta region of Egypt (Stoszek et al 2006). It is 
interesting to note that human HEV strains are close relatives of swine and other animal 
HEV strains.  The zoonotic HEV transmission has been reported in Japan and USA due 
to raw meat consumption, it is likely that animal HEV will adapt to infect humans in 






HCV belongs to the family Flaviviridae and is the only member of the 
Hepacivirus genus. The virus is transmitted through direct contact with the blood or body 
fluids of infected individuals. (Lavanchy 2011, Martins et al 2011). 
  
Hepatitis C is recognized by the World Health Organization (WHO) as a global 
health problem (Fig. 1B). An estimated 3% of the world population (approximately 170 
million) and 4 million in USA alone have been infected with hepatitis C.  In countries 
like the United Kingdom, Scandinavia (0.01% to 0.1%), Americas, Western Europe, 
Australia, and South Africa (0.2% to 0.5%) the prevalence of HCV infection is low. 
Meanwhile, Intermediate prevalence is recorded in Eastern Europe, Mediterranean, 
Middle East, and India. Other countries with intermediate prevalence include Brazil, 
Eastern Europe, parts of Africa, and Asia. Egypt has a high prevalence of HCV infection 
(17% to 26%) besides Hubei, Mongolia, and Pakistan. Among injection drug users 
(IDUs), HCV and HIV coinfection is a major problem. HCV is acquired relatively soon 
after the intravenous drug use. It is estimated that 50% to 90% of IDUs with HIV also 
contract HCV infection. As a result, liver disease from HCV has become the leading  
cause of death in the U.S. in  persons coinfected  with HIV (Gyarmathy and Racz 2011).  
 
4. HCV in Egypt: a case of unintended medical malpractices 
One of the highest prevalence rates (10-13%) of HCV infection in the world is 
found in Egypt (Fig 1.1B). In certain areas such as delta-Nile region, it may rise up to 
40% (Fallahian and Najafi 2011). The epidemic appears to have been initiated during 
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vigorous public-health campaigns using intravenous tartar emetic to eradicate a parasitic 
infection, schistosomiasis, during 1950s through 1982  (Frank et al 2000). Before 1986, 
intravenous tartar emetic was the main schistosomiasis treatment used in Egypt. At that 
time, glass syringes and needles were inadequately sterilized by boiling due to time 
restraints and limited resources. As a result, these treatment campaigns improved 
schistosomiasis-related morbidity but created hepatitis C disease at epidemic proportion 
in Egypt. Consequently, a high incidence of hepatic morbidity and mortality from the late 
complications of HCV infection has emerged , such as chronic hepatitis, cirrhosis and 
hepatocellular carcinoma (HCC) (El-Zayadi et al 2007, Strickland et al 2002). While 
HCV has six major genotypes worldwide (Simmonds et al 2005), the most predominant 
in Egypt is genotype 4 representing over 90% of cases, with 4a as the dominant subtype . 
 
5. Natural History of HCV 
  
 Exposure to infected blood is the main transmission route of HCV including 
Blood transfusion especially that was done before 1992 and intravenous drug use. High-
risk sexual activity, organ transplantation from an infected donor, occupational exposure, 
hemodialysis, and birth to an infected mother, household exposure and intranasal cocaine 
use are other risk factors. According to the Centers for Disease Control and Prevention 
(CDC), HCV transmission through transfusion of contaminated blood products is now 
approximately 1 in 500,000 to 2,000,000 transfusions due to the mandatory 
implementation of HCV screening. High-risk drug (60%) and sexual behaviors (20%) 
were the most common risk factors for acute HCV infection in the U.S. from 1991-1995. 
10% of infections were attributed to other modes of transmission. In  10% of persons 
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with HCV infection no recognized source of infection can be identified, despite the fact 
that most persons in this category are associated with low socioeconomic level(Mellor et 
al 1995). 
a. Acute hepatitis 
 As the majority of acutely infected cases are asymptomatic, acute hepatitis C 
infection is frequently missed clinically; 70% to 80% of the blood transfusion 
documented cases patients were asymptomatic (Chen and Morgan 2006),  20% to 30% of 
adults with acute HCV infection may show clinical symptoms. The incubation period 
ranges from 3 to 12 weeks after first exposure. Symptoms includes malaise, anorexia, 
jaundice and weakness (Czepiel et al 2008). Serum alanine aminotransferase (ALT) 
levels, start to rise 2 to 8 weeks after exposure due to hepatocyte necrosis, and can reach 
levels up to 10-folds the upper normal limits (Vince 2005). The HCV RNA can be 
detected in the serum 1 to 2 weeks after exposure. In some cases (20%), acute hepatitis C 
can be self-limited with symptoms lasting several weeks then subside along with ALT 
and HCV RNA levels decline. Acute HCV infection severe enough to cause  fulminant 
liver failure is rare. The patient becomes positive for anti-HCV antibodies with the onset 
of symptoms 1 to 3 months after exposure and is detected by enzyme immunoassay.   Up 
to 30% of patients also show false negative results for anti-HCV at the onset of their 
symptoms, making HCV antibody an unreliable test in the diagnosis of acute infection. 
Besides, anti-HCV antibody titers can be low or even undetectable in immunodeficient 
patients.  
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b. Chronic hepatitis 
In Chronic hepatitis C, the viral RNA persists in the blood for at least 6 months 
after onset of acute infection. Approximately 75%-85% of infected patients do not clear 
the virus after 6 months and chronic hepatitis develops. Factors affecting the rate of 
chronic HCV infection includes the age at time of infection, gender, ethnicity, and 
jaundice severity during acute infection (Fiel 2010). 
c. Extrahepatic manifestations 
A number of other extrahepatic manifestations has also been demonstrated with 
hepatitis C that include the development of fatty liver (steatosis), autoimmune 
phenomena, peripheral neuropathy, sialadenitis, uveitis, corneal ulceration, and 
polyarteritis  nodosa.(Jacobson et al 2010). 
 
Deposition of circulating immune complexes in small and medium blood vessels 
results in the development of a condition known as Essential Mixed Cryoglobulinemia 
(EMC). EMC presents with rash, arthralgias, and weakness. It is also reviewed  that 
hepatitis C can be found in 95% of all patients with EMC (Jacobson et al 2010). 
Investigators have concluded that hepatitis C may have a causative role in EMC as Anti-
HCV antibodies can be detected in the vessel walls of skin biopsy specimens taken from 
patients with EMC and chronic vasculitis. Furthermore, Interferon (IFN) therapy has 
been shown to lead to symptomatic improvement of both rash and joint pains. However, 
symptoms almost reappear upon cessation of therapy (Pietrogrande et al 2011). Described 
in several reports, the increased incidence of  Non-Hodgkin  B-cell lymphoma occurs in 







Figure 1.1 Viral hepatitis and worldwide impact.  A. Types of hepatitis viruses and 
clinical outcomes of the infections. The arrows with red color show clinical outcomes of 
HCV infection B. Prevalence and distribution of HCV worldwide. C. Proposed 








A positive association between HCV and NHL was first described along with 
cryoglobulinemia using bone marrow biopsy(Marcucci and Mele 2011).  
Glomerulonephritis is also one of the extrahepatic manifestations associated with 
hepatitis C infection. Patients are noted to have significant nephrotic range proteinuria 
and most cases of glomerulonephritis are also associated with cryoglobulinemia. 
Membranoproliferative glomerulonephritis is the most common histologic lesion found in 
those patients(Fabrizi et al 2010). Hepatitis C has also been associated with endocrine 
disorders including an increased incidence of antithyroid antibodies and diabetes 
mellitus. Recently the association has been uncovered between hepatitis C and diabetes 
mellitus, and It was demonstrated that among individuals older than 40 years, patients 
with hepatitis C infection were 3 times or more likely to have type 2 diabetes mellitus 
than those without hepatitis C infection.(Maheshwari and Thuluvath 2011). Also Several 
dermatologic disorders have been described in association with hepatitis C. These include 
porphyria cutanea tarda (PCT) and lichen planus. 
 
d. Hepatocellular Carcinoma (HCC) 
 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the 
world, accounting for approximately one million deaths with an increasing trend of new 
incidences annually (Farazi and DePinho 2006) HCC incidence and mortality are 
increasing, while mortality from other cirrhosis-related complications appears to be 
declining. HCC is also the most prevalent form of primary liver cancer that is 
histologically and etiologically distinct from other forms of primary liver cancer. High 
mortality associated with this disease is mainly attributed to the failure to diagnose HCC 
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patients at an early stage and a lack of effective therapies for patients with advanced stage 
HCC. In the US and Europe, the rise in incidence is mainly due to the current HCV 
epidemic and is expected to continue to increase over the next two decades (Marrero and 
Pelletier 2006). 
  
HCC has a multifactorial etiology,  with affecting disease course and prognosis. In 
most patients (Approximately 70%–90%) with HCC, cirrhosis is a common feature which 
develops after long periods of chronic liver disease that leads to increased fibrous tissue 
and destruction of liver cells, eventuallly allowing tumor development. The risk factors 
for developing HCC include HBV and HCV infection with an incidence of 54.4% and 
31.1% of liver cancer cases globally, respectively, NAFLD, nonalcoholic steatohepatitis 
(NASH), alcoholic liver disease, intake of aflatoxin-contaminated food, diabetes, obesity, 
and some hereditary conditions such as hemochromatosis, and some metabolic disorders. 
The presence of multiple components appears to further drive the hepatocarcinogenic 
process (Yang and Roberts 2010b).   
  
Cirrhosis due to HBV and HCV infection is the major risk factor for developing 
HCC. Cirrhosis facilitates the development of cancerous nodules (Caillot et al 2009). 
Since liver cirrhosis has a central role in the morbidity and mortality associated with 
HCC, establishing the presence and severity of cirrhosis is essential in all patients to 
assess prognosis and proceed with the treatment .  
 
There are several oncogenic pathways involved in HCC like phosphoinositol-3-
kinase/Akt, myc, Wnt/β-catenin, c-Met, and hedgehog (El-Serag and Rudolph 2007, 
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Monga 2009). Some of these pathways are developmental pathways,  indicating  that 
some HCCs may arise from liver stem cells. Presence of liver cirrhosis and the resultant 
growth inhibition  can activate and transform liver stem cells, and according to the work 
done by (Lee et al, 2006) there is an evidence suggesting that a stem-cell gene-expression 
signature exists in a subset of human HCCs (Lee et al 2006c). 
  
e. HCV as a major risk factor for the development of Hepatocellular  
Carcinoma 
 
The main reasons for the increasing incidence of HCC in the developed world are 
chronic HCV infection and Non-Alcoholic fatty liver disease (NAFLD) (Regimbeau et al 
2004). Chronic Infection with hepatitis C virus (HCV) is considered to be a prominent 
epigenetic factor for the development of HCC in most patients. Until now, Direct 
evidence for an HCV carcinogenic role is lacking.  In the work done by (Velosa et al, 
2011), they showed that in compensated HCV-related cirrhosis, sustained virological 
response (SVR) due to Interferon alpha treatment markedly reduces the risk of HCC and 
improves patients ‘survival (Velosa et al 2011).  
 
 In contrast to HBV infection in which, HCC can occur in the absence of cirrhosis 
due to viral integration into host DNA, HCV will not be incorporated into the cellular 
genome. It induces the development of cancer cells, which proliferate out of control 
through different mechanisms including the effect of some proteins of the virus which 
may induce the oncogenic process. Furthermore, It has been also proposed that the virus 
acquires its oncogenic effect via oxidative stress, and by activation of different oncogenic 
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signal pathways. The studies done by (Fishman et al, 2009)(Fishman et al 2009) and (Hu 
et al, 2009)(Hu et al 2009) showed that Differences were found in HCV core gene 
sequences between HCC patients and patients with early-stage liver disease with and 
without cirrhosis. Other factors may have a role in the development of liver carcinoma 
besides the virus determined factors, like the host reaction, the deficient tumor cell 
eliminating capacity may also be a factor (Szalay 2010). 
 
Due to the fact that most HCV-related HCC occurs on top of severe fibrosis or 
cirrhosis it is also proposed that the mechanism of carcinogenesis is possibly indirect, in 
such way that tissue damage, regeneration and repair are required, rather than a direct 
viral oncogenic effect or the viral induced inflammatory response (Nash et al 2010). In a 
study done by marshal et al 2005, It was shown that hepatocytes from patients with 
chronic HCV infection are arrested in G1 and can undergo replicative senescence, 
predisposing to malignancy(Marshall et al 2005).  
 
Since chronic HCV infection is a dominant risk factor for the development of 
HCC, understanding the molecular basis of HCV-induced CSC-like properties in hepatic 
cells will advance our ability to prevent and treat HCC. In adult liver, hepatic 
stem/progenitor cells (HSPCs) predominantly reside in bile duct (canal of Herring).  
These cells are quiescent with a low proliferating rate and are activated only when the 
mature epithelial cells of the liver are continuously damaged or lost.   In severe acute or 
chronic injury, proliferation and self-renewal of HSPCs are significantly enhanced.  
Although HCV is a noncytopathic virus, the infection causes loss of hepatocytes and 
significant reduction in regenerative capacity of the liver that ultimately results in 
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cirrhosis. These observations clearly indicate that during long-term HCV infectious 
process, the normal function of liver stem/progenitor cells are lost or impaired. 
 
Telomere length and chromosomal stability in proliferating cells such as 
hepatocytes  are maintained in part by telomerase. Shortening of telomere is therefore 
thought to reduce the regenerative capacity of organs during aging and chronic disease 
limiting proliferation. In the study done by Wiemann et al, 2002 (Wiemann et al 2002), it 
was shown that of in a cirrhotic liver, telomeres are significantly shorter than in a 
noncirrhotic one, and this shortening is correlating with fibrosis progression. Therefore, 
telomere dysfunction and alterations in the micro- and macro environment that stimulate 
cellular proliferation  has been proved  to affect development of HCC. Therefore, 
reduction in hepatocyte proliferation is thought to enhance cancer formation in cirrhotic 
livers. This observation was further supported by an experiment in a rat model in which 
hepatocyte proliferation was inhibited by chemicals and carcinogen-induced liver tumor 
formation was accelerated (van Gijssel et al 1997). Cirrhosis also activates stellate cells 
leading to an increase in the production of growth factors, cytokines,  and oxidative stress 
products (Bataller and Brenner 2005) which all have been shown to affect hepatocyte 
proliferation and so could have a role in tumor formation (El-Serag and Rudolph 2007). 
Activation of Akt signaling In liver cirrhosis can promote tumor formation by 
suppressing transforming growth factor (TGF)-β–induced apoptosis. Activation of this 
pathway has also been linked to activation of β-catenin  signaling,  further supporting  the 
hepatocarcinogenic process (El-Serag and Rudolph 2007). 
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In addition to all mentioned factors that contributes to the development of HCC, 
the molecular alterations occurring in checkpoints that control DNA damage like  the p53 
tumor suppressor gene and inactivation of the p27 cell cycle regulator have been 
described, which may have a role in promoting tumor formation in the cirrhotic 
liver(Matsuda 2008). 
  
6. HCV Genotypes and quasispecies 
 
The high spontaneous mutational rate that is characteristic of many RNA viruses 
results in a considerable heterogeneity throughout the HCV genome. The 5′ and 3′ UTRs 
are the most highly conserved regions of the genome; and the most variable are the 
envelope regions (E1 and E2). Genetic heterogeneity has been classified under two 
headings: genotype and quasispecies. Genotype represents the genetic heterogeneity of 
the virus between patients, and Quasispecies represent the genetic heterogeneity of the 
HCV population within an individual patient (Klenerman et al 2000). 
 
Hepatitis C virus has highly related but meanwhile distinct six genotypes, and 
various subtypes with different geographic distribution and complex nomenclature. Since 
The C, NS 3 and NS 4 domains are the most highly conserved regions of the genome, 
these proteins are used as capture antigens for broadly reactive tests for antibodies to 
HCV (Zuckerman et al 2001). HCV genotyping system based on PCR of the core region 
with genotype specific PCR primers for determination of HCV genotypes 1a, 1b, 2a, 2b, 
3a, 3b, 4, 5a, and 6a were developed(Ohno et al 1997). 
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The second component of HCV genetic heterogeneity are the quasispecies. 
Quasispecies are heterogeneous sequences of the HCV genome within a single infected 
person that result from mutations during viral replication. The rate of nucleotide changes 
varies significantly among the different genomic regions, with an overall mutation rate of 
0.144% to 0.192% nucleotide changes per year. The highest proportion of mutations has 
been found in the E1 and E2 regions at both the nucleotide (1.2%–3.4%) and the amino 
acid (1.4%–2.7%) levels, particularly in the hypervariable region (HVR) at the amino 
terminal end of E2 (Farci et al 2000). Even though this region represents only a minor 
part of the E2/NS1 region, it accounts for approximately 50% of the nucleotide changes 
and 60% of the amino acid substitutions within the envelope region. Recent studies have 
shown that the rate of mutations within the HVR may be accelerated by interferon 
therapy (Enomoto et al 1995).The quasispecies nature of HCV may be one of the 
mechanisms by which the virus escapes immune responses. Furthermore, strain-specific 
viral factors, not distinguishable on the basis of genotype, may play a significant role in 
disease severity, thereby potentially explaining different courses of disease.  
 
 
7. Diagnosis of HCV 
 
There are two types of tests used in the diagnosis HCV infection. Those include 
serologic assays that detect hepatitis C virus specific antibodies (anti-HCV) in patients 




a. Serological tests 
 
 Screening using HCV Enzyme immunoassay (EIA) to detect HCV antibodies is 
routinely done for all blood donors or persons at risk of contracting the disease. The two 
enzyme immunoassays (EIAs) approved by the U.S. Food and Drug Administration 
(FDA) for clinical use, are Abbott HCV EIA 2.0 (Abbott Laboratories, Abbott Park, IL) 
and ORTHO HCV Version 3.0 ELISA (Ortho-Clinical Diagnostics, Raritan, NJ).  
Another enhanced chemiluminescence immunoassay (CIA) is VITROS Anti-HCV assay, 
(Ortho-Clinical Diagnostics, Raritan, NJ). IF The EIA test for HCV antibody is positive, 
additional testing with recombinant immunoblot assay (RIBA) is done to confirm the 
diagnosis (Ghany et al 2009, Puoti et al 2009).  
  
b. Molecular tests 
 
 Several commercial assays either qualitative or quantitative are available for the 
detection of HCV RNA. Because HCV antibodies takes several weeks to develop, EIA 
results could come falsely negative in recently infected individuals. PCR can detect HCV 
RNA in patient’s serum within 7 to 21 days after exposure and can be used to confirm the 
diagnosis and also to monitor the patient’s treatment response. Recently, because of the 
highly sensitive real time polymerase chain reaction (PCR)-based assays and 
transcription-mediated amplification (TMA) assays that can detect as low as 10-50 
IU/mL,  monitoring patient’s response during therapy became easier. 
 
In certain situations when patients can not produce anti-HCV antibody, HCV 
RNA testing is required especially in immunosuppressed or immunoincompetent patients 
17 
who underwent organ transplant, are on dialysis, are taking corticosteroids, or have 
agammaglobulinemia .  Similarly, the anti-HCV may represent a false-positive reaction 
due to previous HCV infection, or another liver condition like alcoholism, autoimmunity 
or iron overload (Hemochromatosis). HCV RNA testing in these situations has a 
confirmative role (Scott and Gretch 2007).  Because the patient response to anti-HCV 
therapies available differ by and is directly related to the viral genotype, genotyping 
Assays are employed to determine the  appropriate therapeutic approach and required 
duration of therapy (Scott and Gretch 2007). 
 
c. Liver biopsy 
 
It is crucial to grade the liver disease in patients with hepatitis C to help guide 
treatment. The role of serum aminotransferase levels, HCV viral load, and hepatitis C 
genotype is negligible in predicting underlying liver histology. Therefore, it is 
recommended in the initial evaluation of all hepatitis C patients that liver biopsy to be 
performed to provide Information that can help exclude other causes of liver disease, 
determine the rate of progression of disease, and help in monitoring therapies if the 
patient is experiencing significant adverse effects. Usually persons infected with 
genotypes 2 and 3 respond well to standard therapy, and treatment can be started without 
liver biopsy in those patients. The extent of necroinflammatory activity,  fibrosis or the 
presence of cirrhosis are important determinants whether treatment can be effective or 
not, and also gives an idea about malignant transformation possibility in patients with 
advanced cirrhosis (Kleiner 2005).  
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8. Molecular Biology of HCV 
 
 The viral structural proteins are encoded by the N-terminal part of the ORF, 
whereas the nonstructural proteins are coded for by the remaining portion of the ORF 
(fig.1.2a). Sequence motif-conserved RNA protease-helicase and RNA-dependant RNA 
polymerase (RdRp) are found at similar locations in the polyproteins of all of the 
Flaviviridae. In addition, all Flaviviridae share similar polyprotein hydropathic profile, 
with flaviviruses and hepaciviruses being closer to each other than to pestiviruses. The 
ORF is flanked in 5′ and 3′ by untranslated regions (UTR) of 95–555 and 114–624 nt in 
length, respectively, which play an important role in polyprotein translation and RNA 
replication (Brass et al 2006, Lindenbach and Rice 2005).  
 
The virion contains a positive strand RNA genome encoding a single polyprotein 
of 3010 aa.   The polyprotein is cleaved by cellular and viral proteases into structural 
(core, and envelope glycoproteins E1 and E2) and nonstructural proteins (p7, NS2, NS3, 
NS4A, NS4B, NS5A and NS5B) (Fig.1.2b).  Translation of the polyprotein is mediated 
by a unique internal ribosome entry site (IRES) that consists of almost the entire 5’ 
noncoding region and a few nt of the downstream of the initiator AUG codon.   
 
a. Attachment and entry of HCV into cells  
 
 The primary target for HCV replication is the liver hepatocytes . HCV E2 attach 
with high affinity to CD81 external loop (Fig.1.1C). The low density lipoprotein receptor 
(LDLR) and scavenger receptor class B type I (SR-BI) have been proposed as 
components of a putative HCV receptor complex. CD81 is a member of the tetraspanin 
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protein family that interacts with EWI-2; A cleavage product of which was recently 
reported to inhibit HCV entry by reducing the association of E1–E2 with CD81(Schuster 
and Baumert 2009). This cleavage product was not found in hepatocytes, leading to the 
suggestion that its expression may explain their inability to support HCV entry in various 
non-permissive cell types. CD81 can also associate with Claudin-1 in a cholesterol-
dependent manner forming complexes that is essential for HCV entry (Meertens et al 
2008). Recent Studies supported the idea that lipoproteins play an important role for viral 
cell entry (Regeard et al 2008). In addition association to high density lipoprotein (HDL) 
enhanced SR-BI guided cell entry which may be due to protection of viral particles from 
neutralizing antibodies (Helle and Dubuisson 2008, von Hahn and Rice 2008). 
 
 CD81, Claudin-1 and SR-BI expression in normal and HCV-infected human 
livers is limited to the basolateral–sinusoidal hepatocellular surface (Jia et al 2008) that 
also contains CD81–Claudin-1 complexes. In addition, CD81 is expressed mainly at the 
basolateral surface and is excluded from tight junctions with CD81–Claudin-1 complexes 
formed at the same surface. Concluded from that, HCV enters the liver through the 
sinusoidal blood, to come into direct contact with the basally expressed  receptor 
complexes (Reynolds et al 2008). Following attachment The virion envelope fuses with 
cellular membranes delivering the nucleocapsid to the cytoplasm. After entry of the viral 
genome, translation occurs in the cytoplasm producing a precursor polyprotein, which is 
then cleaved by both cellular and viral proteases into structural and nonstructural 




Figure 1.2. Genomic organization of HCV and polyprotein processing scheme.  A. The 
5’NCR, a single, open reading frame that encodes 3010 aa precursor polypeptide and its 
processing by cellular and viral protease into individual proteins are shown. ARF, 
alternate reading frame protein  B. Structure of the 5’NCR. Four structural domains (I-
IV), polypyrimidine (Py) motifs, multiple AUGs and pseudoknot structure (PK) are 
shown. SI and SII are stems of the PK. Translation of the ORF starts at AUG342.  C. 
Base pairing of miR-122 at two sites within Domain I of the ‘NCR are shown (adapted 









membranes. Replication occurs in the cytoplasm by the synthesis of full-length negative-
strand RNA intermediates that act as a template for viral RNA synthesis. Assembly of 
Progeny virions follows by formation of cytoplasmic vesicles that buds through 
intracellular membranes and Finally, mature virions are released extracellularly by 
exocytosis (Stamataki et al 2008).  
 
b. Molecular mechanism of HCV protein synthesis: a unique internal 
ribosome  entry site/segment (IRES)  
 
Hepatitis C virus (HCV) polyprotein translation is mediated by an internal 
ribosome entry site (IRES) (Wang et al 1995) . A 330 nt, located in the 5′ untranslated 
region (UTR) of the genome, controls translation by a mechanism distinct from other 
canonical mRNAs. In eukaryotic mRNA The 5′ 7meG-cap structure first assembles with 
eukaryotic initiation factor 4F (eIF4F). Subsequently, a 43S ribosomal complex, 
composed of the 40S subunit, eIF3, ternary complex (eIF2·Met-tRNAiMet·GTP), and 
other factors, binds to eIF4F at the 5′ end and then scans the 5′ UTR of the mRNA in an 
ATP-dependent manner until the AUG is positioned the in the ribosomal start site to form 
the 48S complex. Subsequent GTP-dependent release of initiation factors and 60S 
subunit joining , followed by first peptide bond formation, complete initiation of 
translation  (Otto and Puglisi 2004).  
 
HCV IRES-mediated translation initiation is independent of the 5′ cap structure or 
ATP-dependent scanning and requires only a subset of the canonical initiation factors. 
The HCV IRES direct internal initiation by recruiting translation initiation complexes 
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directly to the AUG start codon without scanning. Pestova et al.,1998 demonstrated by 
Reconstitution of IRES initiation that the IRES assembles on purified 40S subunits 
devoid of initiation factors (Pestova et al 1998). This IRES·40S binary complex is formed 
near the AUG start codon. The AUG docks in the ribosomal start site after addition of 
only eIF3 and ternary complex yielding a 48S complex without eIF4F during the first 
step of translation.(Pisarev et al 2005) The HCV sequence and secondary structure are 
highly conserved among viral isolates. Based upon phylogenetic comparison to the 
related pestiviruses and GB virus-B, the predicted IRES secondary structure was 
constructed using chemical and enzymatic probing and mutagenesis (Zhao and Wimmer 
2001). The IRES motifs structures of the HCV, pestivirus, and GB virus-B are similar 
with regions of conserved sequences. Some sequence differences exists, but the main 
structural and functional elements are conserved in all HCV-like IRESs, with the same 
mechanism of initiation.  
 
The HCV 5′NTR has four structural domains, designated I to IV. The most 
complex is domain III is, having a pseudoknot, multiple helices, and hairpin domains 
IIIa–IIIf. Domains IIIa–IIIc and IIIe–IIIf form four-way helical junctions, folding of 
which is dependent on physiological concentrations of divalent metal ions (Melcher et al, 
2007)(Melcher et al 2003). This secondary structure and atomic details of IRES 
architecture was confirmed by computed three-dimensional structures of IRES domains 
(Kieft et al 2002, Lukavsky 2009). 
 
The Role of these different IRES domains functions during initiation is not fully 
understood but likely involves regulation of initiation complex assembly. The recruitment 
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of the translation initiation complexes is mediated by HCV IRES Domain III with its 
basal portion binding with high affinity to the 40S subunit (Kieft et al 2002), and also 
contacting ribosomal proteins involved in the binding and positioning of mRNA and 
tRNA(Otto et al 2002). The apical portion of domain III (IIIb) interacts with eIF3 
involved in mediating ternary complex stability and subunit assembly (reviewed in 
(Merrick 2000). Domain II interacts with ribosomal protein S5 protruding into the 
ribosomal start site, leading to a conformational change in the 40S subunit, suggesting 
roles in both mRNA and tRNA regulation (Fletcher et al 2002).  Domain IV controls 
Proper positioning of the initiation codon. 
 
Several factors influence the Activity of the HCV IRES. Most important is the X-
tail at the 3’ end of the HCV genome that appears to enhance IRES-dependent translation 
by an unknown mechanism (Ito and Lai 1997). Some cellular factors have been 
demonstrated to bind to the HCV IRES  stimulating translation. These cellular factors 
include polypyrimidine- tract-binding protein (PTB) (Ali and Siddiqui 1995), the La 
antigen (Ali and Siddiqui 1997), and heterogeneous nuclear ribonucleoprotein L(Hahm et 
al 1998).  
  
c.  3′ UTR  
      
The 3′ UTR contains approximately 225 nt organized in three regions including a 
variable region of approximately 30–40 nt, a long poly(U)-poly(U/UC) tract, and a highly 
conserved 3′-terminal stretch of 98 nt (3′ X region) that includes three stem-loop 
structures SL1, SL2 and SL3. The 3′ UTR interacts with the NS5B RdRp and with two of 
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the four stable stem-loop structures located at the 3′ end of the NS5B-coding sequence. 
The 3′ X region and the 52 upstream nt of the poly(U/C) tract were found to be essential 
for RNA replication, whereas the remaining sequence of the 3′ UTR appears to enhance 
viral replication(Tellinghuisen et al 2007). 
 
d.  Viral proteins and their functions 
 
The HCV core protein forms the viral capsid and is composed of an N-terminal 
RNA-binding domain I (DI), a hydrophobic central domain (DII) that supports the 
association with lipid droplets (LDs), and the C-terminal domain that serves as signal 
sequence for E1 (Boulant et al 2006). In addition two variant forms of core protein  have 
been described (Eng et al 2009). These core variants are not required for viral replication, 
but it is unknown yet if they contribute to pathogenesis.  
The envelope proteins (E1 and E2) are heavily glycosylated type I transmembrane 
proteins with E1 maturation requiring the coexpression of E2. E1 and E2 form  
noncovalently linked heterodimers forming a receptor on the surface of the HCV particle  
(Lindenbach and Rice 2005). The p7 protein act as an ion channel known as viroporin 
and is required for HCV assembly and release. The NS2 protein does not have a direct 
role in viral replication, but is required  for the production of infectious virus particles 
(Tellinghuisen et al 2007).  
 
HCV genome encodes four viral enzymes; NS2-3 autoprotease and NS3-4A 
serine protease, NS3 helicase and NS5B RNA-dependent RNA polymerase, all of which 
are essential for HCV replication and infectivity (Chevaliez and Pawlotsky 2006). 
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Inhibiting the activity of NS3 serine protease, stalls the replication of HCV. Therefore, 
the NS3 serine protease has become an interesting target for viral therapeutics. NS3 is a 
multifunctional protein, with an N-terminal serine protease domain and a C-terminal 
RNA helicase/NTPase domain. It cleaves the viral polyprotein at four junctions and its 
activity is essential for the generation of components of the viral RNA replication 
complex and helps virion assembly. The serine protease domain is a member of the 
chymotrypsin serine protease family. NS4A is a small (54-amino-acid) protein that 
anchors NS3 to cellular membranes through an N-terminal hydrophobic peptide. The 
serine protease domain  requires coordination of Zn2+ by three cysteine residues distal 
from the active site for Proper folding.  In addition, the NS3-4A protease activity has 
been implicated in blocking the host cell's ability to mount an innate antiviral response 
(Shi and Lai 2006). 
 
The NS4B protein is a membrane protein with a complex structure. 
Overexpression of this protein leads to membrane alterations, indicating that it is 
probably required for the formation of the membrane-associated viral replication complex 
(Brass et al, 2006).(Brass et al 2006) NS4B was also described to bind to viral RNA and 
compounds enhancing RNA replication (Glenn 2006). NS5A is another key factor for 
RNA replication and assembly expressed in a hyperphosphorylated form, which seems to 
be important for production of infectious virions(Tellinghuisen et al 2007). 
Hyperphosphorylation of NS5A is suggested to reduce its interaction with  the human 
vesicle-associated membrane protein-associated protein A ( hVAP-A) which acts as a 
vesicle sorting protein, directing nonstructural proteins to lipid rafts (Poenisch and 
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Bartenschlager 2010). Several cellular proteins have been described to bind to NS5A. 
Cyclophilin A (CypA) is one of those proteins, which has become an important target for 
antiviral therapy. 
 
e.  Mechanism of HCV Replication 
 
The mature nonstructural proteins and a few cellular proteins forms a membrane 
associated replicase complex and initiate replication of the genome at the 3’ end for 
synthesis of negative strand RNA, which in turn, serves as a template for producing more 
positive strand genome(Tellinghuisen et al 2007). These dynamic processes cause 
extensive rearrangements in the intracellular membrane structures and alterations in 
signaling pathways in infected cells forming a membrane-associated replication 
complex(Lindenbach and Rice 2005).  The formation of such a complex is a feature 
typical of plus-strand RNA viruses like poliovirus or Flaviviruses(Brass et al 2006) and it 
permits the production of viral proteins and RNA in an isolated compartment. As NS4B 
is a major component of the viral replication complex and has an RNA-binding activity, 
it facilitates attachment of the viral positive strand RNA. After NS5B, the RNA-
dependent RNA polymerase is recruited by Cyclophilin A, to the viral replication 
complex, Replication  replication results in  negative strand intermediate which is further 
used to make the positive strand progeny that incorporates into new virus particles. The 
viral helicase unwind newly transcribed positive strand form  its template negative strand 
and this positive sense strand becomes available for translation, transcription or 
packaging in new virions (O'Leary and Davis 2010). 
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f.  Evasion of immune system by HCV 
 
Viral persistence is attributed to HCV ability to evade the adaptive and innate 
components of the host's immune system (Fig.1.3). IFN is a major effector of innate 
antiviral immunity and is naturally produced in response to viral infection when viral 
pathogen-associated molecular patterns (PAMPs) are recognized as nonself and are 
bound by cellular pathogen recognition receptors (PRRs), including Toll-like receptors 
(TLRs) and the RIG-I-like receptors (RLRs). Within hepatocytes, RIG-I is a major PRR 
of HCV infection wherein PAMP interactions serve to trigger intracellular signaling 
cascades in the infected hepatocyte to drive IFN production and the expression of 
interferon-stimulated genes (ISGs). ISGs function to limit virus replication, modulate the 
immune system, and to suppress virus spread (Guobuzaite et al 2008). The hepatic innate 
immune response is triggered when the infected cell recognizes a  pathogen-associated 
molecular patterns or PAMP within the virus as nonself through the actions of cellular 
pathogen recognition receptors or PRRs. PRRs include Toll-like receptors (TLRs), 
melanoma differentiation-associated gene 5 (MDA5) and the RIG-I-like receptors 
(RLRs). The RLRs have a C-terminal RNA helicase domain that has RNA-binding 
activity. Of this family, only RIG-I and MDA5 have N-terminal tandem caspase 
activation and recruitment domains (CARDs) that are necessary for RIG-I function and 
bind long stable double-stranded RNA ligands different from RIG-I ligands. RIG-I is a 
main PRR in HCV infection) (Liu and Gale 2010).  The PAMP/PRR interaction triggers 
signaling cascades that induce the expression of antiviral effector genes in the infected 
hepatocytes driving IFN production which in turn stimulates the the expression of 
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interferon-stimulated genes (ISGs) both within the infected cell and non-infected cells 
that respond either locally or systemically to the secreted IFN. ISGs are responsible for 
inhibiting virus replication, modulating the immune system, and preventing virus spread. 
During HCV infection, RIG-I and TLRs signaling  pathways  promote Interferon 
regulatory factor- (IRF-) 3 and nuclear factor-kappa B (NF-κB) nuclear translocation and 
transactivation functions through its CARDs signaling domain interaction with the 
downstream molecule, mitochondria-associated MAVS (also called IPS-1, VISA or 
CARDIF) (Loo et al 2008) (Liu and Gale 2010). 
 
The HCV NS3 is a multifunctional helicase/protease protein.  It harbors N-
terminus protease and C-terminus NTPase/RNA helicase domains.  The protein plays a 
remarkable role in the evasion of host innate immunity in addition to its critical roles in 
polyprotein processing and replication.  HCV NS3/4A efficiently cleaves two pathogen 
associated molecular pattern (PAMP) receptors, RIG-I  and IPS-1 (Tasaka et al 2007). In 
addition, Replication of HCV RNA causes strong ER stress (Waris et al 2005). Among 
the HCV proteins, core, E1 and NS3, NS5A are shown to be potent inducer of reactive 
oxygen species (ROS); their expression lead to DNA damage and induction of STAT3 
and NFkB (Waris et al 2005);(Waris et al 2002a). 
 
9. Treatment of the HCV infection  
 
Although there are many drugs and HCV protein inhibitors in the pipeline, 












Figure 1.3. Current model for HCV-resistance and immune invasion 
 
 







the HCV strains.  However, more than half of the patients do not show sustained viral 
clearance. With these drugs (Pereira and Jacobson 2009, Vermehren and Sarrazin 2011).  
Many investigators were able to developed vaccines against HCV proteins but these 
vaccines have been shown to be ineffective against preventing the viral infection.  
 
The primary goal of therapy in the hepatitis C patient is to achieve a sustained 
viral response, which is defined as undetectable HCV RNA 6 months after termination of 
antiviral therapy. Second goal is improvement in histologic findings and quality of life 
and the prevention of HCC. Patients with persistently abnormal liver enzyme test results, 
detectable HCV RNA, and an abnormal liver biopsy result are candidates for antiviral 
therapy. Several regimens have been licensed in the United States for the treatment of 
chronic hepatitis C. These regimens include IFN-alfa-2a, IFN-alfa-2b, IFN-alfa-con 
(consensus)-1, pegylated IFN-alfa-2b, combination IFN-alfa-2b and ribavirin, and 
combination pegylated IFN-alfa-2b and ribavirin. Pegylated IFN-alfa-2a alone and in 
combination with ribavirin is currently awaiting approval by the US Food and Drug 
Administration . 
 
The current FDA-approved standard of care (SOC) for HCV infection consists of 
weekly injections of pegylated interferon-α along with twice-daily oral ribavirin (Peg-
IFN/RBV regimen). The sustained viral response (SVR) with this SOC depends on strain 
of the virus as well as host attributes such as genetic variations.  For example, patients 
infected with genotype 1, the SVR rate is generally <50% with 48 weeks SOC treatment 




A number of drugs that include the specifically targeted antiviral therapies for 
hepatitis C (STAT-Cs), and cellular targets against HCV (CTACs) are at various stages 
of clinical trials or have been stopped because of their adverse effects, multiple drug 
resistance or ineffectiveness in the patients (Kieffer et al 2010b).  The most successful 
among STAT-Cs include drugs against NS3 protease/helicase (telaprevir, boceprevir), 
NS5B polymerase (nucleoside and non-nucleoside analogues) and NS5A protein (BMS-
790052).  
 
The use of telaprevir or boceprevir, in combination with Peg-IFN/RBV regimen 
was reported to increase the SVR rate by 20% in shorter duration (within 24 weeks) as 
compared the SOC alone (48 weeks) in patients infected with HCV genotype 1.  
Similarly, impressive potency of NS5A inhibitor (BMS-790052) has been shown in 
clinical trial (Gao et al 2010).   
 
With all these successful stories and enthusiasm, cure for the HCV infection has 
been elusive not only because of adverse effects on patients but also due to emergence of 
drug-resistance (Fridell et al 2010, Kieffer et al 2010b, Liu et al 2009, Pockros 2010). 
Anemia (up to 37% with telaprevir and up to 56% with boceprevir), skin problems for 
telaprevir (rash and pruritis) and dysgeusia for boceprevir in addition to the influenza-like 
symptoms, cytopenias and depression caused by the SOC are major hindrance in 
successful treatment.   
 
 The viral variants with reduced susceptibility to STAT-Cs occur naturally at low 
levels due to error-prone HCV replication mechanism, and can be selected in patients not 
32 
responding to STAT-C/SOC treatment. Susceptibility of HCV against these drugs 
diminishes due to gradual incorporation of mutations in the virus that have been 
demonstrated during in vitro and in vivo testing.  These drugs have huge potential for 
misuse due to prescribing physician’s poor understanding of the therapeutic populations, 
inadequate viral-assay testing, poor side-effect management, and lack of monitoring for 
antiviral resistance (Thompson and McHutchison 2009, Toyoda et al 2010).  
 
Statins are well tolerated by patients with HCV and may be added in standard 
therapy as a cellular target for anti HCV (CTAC) therapy.  More recently, Himmelbach et 
al. (Himmelsbach et al 2009) demonstrated that Sorafenib, an FDA and EU approved 
drug for the treatment of HCC also inhibits HCV replication in cell culture. Sorafenib has 
been shown as a potent inhibitor of c-Raf that interacts with the HCV NS5A. The CTAC 
inhibitors (e.g. NIM811, Debio 025) for the HCV protein-interacting partners such as 
cyclophilins A and B are also in clinical trials. However, due to adaptive mutations in the 
HCV proteins, the drug-resistance is inevitable as reported in a number of studies (Yang 
et al 2008).  
 
HCV induced stem cell-like features may contribute to the long-term persistence 
of HCV and HCV-induced aggressive HCC. Therefore, new CTAC inhibitors whose 
potencies are not compromised by the HCV adaptation and drug cocktail with diverse 
mechanisms of action are needed to combat HCV infection.  Such multi-dimensional 
approach is likely to be effective against both the HCV and the HCV-led initiation of 
liver carcinogenesis.  
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10. Models used for investigation of HCV infectious processes 
 
Humans and Chimpanzees are the only known natural host of HCV. However, 
over three decades, investigators have tried to develop various models to study HCV 
infection and replication process.  The most important ones that contributed in 
understanding the viral infection are as described below: 
 
a.  HCV replicons  
      
 The HCV replicons were constructed from cDNA  isolated from the liver of  
subjects chronically infected with a genotype 1b strain and consisted of the HCV 5' NTR 
and the genes coding for the capsid protein fused in-frame with the selectable marker 
gene, neomycin phosphotransferase (Neo), which upon expression confers resistance to 
the cytotoxic drug G418 and ending with HCV 3' NTR HCV 3' NTR. (Figure.1.4) The 
IRES element from encephalomyocarditis virus (EMCV), drives translation of the HCV 
non-structural proteins (Blight et al, 2006) (Blight and Norgard 2006)  . Huh-7 cells 
transfected with transcripts synthesized in vitro and selection with G418 enabled isolation 
of a low number of surviving cell colonies.  
 
Many improvements to the replicon system allowing the establishment of 
transient replication assays for other HCV genotypes eg. 1a, 1b, and 2a have been made. 
The identification of adaptive mutations that enhance HCV (huh 7.5) led to the 
development of replication competent full-length genomes. More recently, the HCV 
subgenomic replicons cell tropism has been expanded to non-hepatoma cell lines and  
mouse hepatocytes. Recently, the identification of genotype 2a-derived replicons 
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efficiently replicating in cell culture needless of adaptive mutations has enabled the 




 As the only animal model available, the chimpanzee  has been commonly used to 
study mechanisms of acute and chronic HCV infection and these studies have greatly 
contributed to the current understanding of HCV infection, including immunity and 
pathogenesis (Bukh 2004). However, there are many drawbacks in the chimpanzee model 
that limit its use. First of all, HCV-infected chimpanzees rarely develop chronic liver 
disease to the same extent seen in HCV-infected humans (Hiraga et al 2007), making the 
chimpanzee not an ideal model for studying the mechanisms of HCV pathogenesis. 
Moreover, chimpanzees are expensive, difficult to handle, and need special housing and 
care in appropriate non-human primate research facilities. These limitations of the 
chimpanzee model have stimulated progress toward developing alternative animal 
models for HCV research. 
 
c. Mouse models 
 
Due to its limited permissiveness in animals, HCV was only  studied in humans or 
in chimpanzees. Recently, a new chimeric mouse model was developed to be permissive 
for HBV and HCV infection. The new mouse model, uPA+/+-SCID represent mice with 
a transgene-induced liver disease. Mice are transplanted with primary human hepatocytes 
early after birth. These human hepatocytes were able to integrate in the parenchyma and 
progressively repopulate the diseased mouse liver with all their normal metabolic 
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functions preserved. The successfully transplanted mice were then  infected with HCV 
(Barth et al 2008). This model will allow in vivo expression of HCV proteins and provide 
an important tool for understanding virus–host interactions, and pathogenesis of HCV 
infection as many of these mouse models exhibit aspects of HCV-related liver disease. 
They also will help  studies to evaluate the  safety and efficacy of new antiviral 
compounds against HCV. 
 
d. JFH1 infectious clone 
 
Studying many aspects of the hepatitis C virus (HCV) life cycle could not be 
reproduced in cell culture. This obstacle has slowed research and hampered progress on 
the development of effective antivirals and vaccines against HCV. Recently, Robust 
production of infectious HCV in cell culture has been achieved using a unique genotype 
2a strain  HCV genome derived from the blood of a Japanese patient with fulminant 
hepatitis C (JFH-1) (Berke and Moradpour 2005, Cai et al 2005, Wakita et al 2005). 
Moreover, the virus particles generated from the JFH-1 clone(fig.1.4) proved to be 
infectious in vivo both in chimpanzees and in chimeric mice containing transplanted 
human liver populations (Lindenbach et al 2006, Wakita et al 2005). By introducing 
multiple adaptive mutations this infectious HCV genotype 1 could also be produced and 
maintained in cell culture and The full-length JFH-1 RNA was transfected into Huh7 
cells. Subsequently, viral RNA efficiently replicated in transfected cells producing nearly 
10(5) infectious units per milliliter within 48 hours and viral particles were secreted and 
was able to infect naive Huh7 cells (Zeisel and Baumert 2006). 
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11. Hypotheses and Aims 
  
While maintaining their phenotypes by self-renewal process, the cancer stem-like 
cells (CSCs) function as seed elements of the solid tumors including hepatocellular 
carcinoma. Because HCV is a dominant risk factor for the HCC development and HCCs 
contain cells with stem cell gene-expression signatures (discussed above), we 
hypothesize that long-term infection of HCV causes phenotypic changes. These changes 
might be due to altered expression of oncogenes and cancer stem cell markers. Keeping 
in view of the above-described problems, my thesis work was focused on three major 
specific aims: 
i. To investigate if HCV-expressing cells undergo phenotypic changes and 
exhibit enhanced expression of oncogenes (e.g. c-Src) and putative cancer 
stem cell markers  
ii. To investigate possible mechanism of the HCV-induced hepatocarcinogenesis 










Figure 1.4. JFH1 RNA represents genotype 2, isolated from a Japanese patient with 
severe acute hepatitis (Wakita et al 2005)  and is currently being used as infectious 
model. The second model is the subgenomic replicon system in which the sequence from 
core through NS2 is replaced with neomycin resistance gene followed by 
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES). The HCV IRES 
translates Neomycin phosphotransferase (Neor) gene that confers resistance to G418 drug 
in tissue culture. The EMCV IRES translates NS3-NS5B that are required for the viral 
replication. The replicon expresses NS5A-GFP chimeric protein. Using this model, we 
have studied mechanism of viral replication, and function of viral and cellular proteins on 
the HCV life-cycle. proteins’ Huh-7 or Huh7.5 cells transfected with the replicon 













HCV is one of the most important human pathogens.  Its global presence and 
severity of the liver diseases have proven to be detrimental. Likewise, its economic 
burden is huge. The research activities in academic institutions and pharmaceutical 
laboratories have been focused for years on the development of novel therapeutic agents 
for hepatitis C.   The HCV field has taken a giant leap during last ten years by advancing 
HCV culture methods, unraveling molecular mechanism of HCV entry and infectious 
processes, and by developing new classes of HCV inhibitors.  However, these 
developments are not enough to fully understand HCV pathogenesis. Furthermore, owing 
to its quasispecies nature due to its high mutation rate, viral resistance is a major issue for 
vaccine and drug development.  Till now, current treatment approaches are not curative.  
While HCV on its own is a huge medical problem, the association between HCV 
infection and hepatocellular carcinoma is an added insult to the injury.  
 
The work presented in this thesis provides a novel concept of HCV virology by 
delineating relationship between HCV infectious process and development of cancer stem 
cell-like traits in the host cells.  Using RNA interference for targeting a putative stem cell 
marker (DCAMKL-1), which is known to be involved in colon and pancreatic cancer, 
this work has set a precedent that delivery of DCAMKL-1 antagonist by gene therapy 
technology or by small molecule inhibitors will help in reducing the risk of HCV-induced 










Chapter Two: Hepatitis C Virus-Induced Cancer Stem Cell-like Signatures 
  
1.    Introduction 
 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy 
worldwide, accounting for approximately one million deaths annually (Farazi and 
DePinho 2006, Parkin 2001, Yang and Roberts 2010a).  The high mortality associated 
with HCC is attributed to the failure of early stage diagnosis and lack of effective 
treatment for patients with advanced stage HCC (Farazi and DePinho 2006, Woo et al 
2010, Wu et al 1996). Chronic infection with hepatitis C virus (HCV) is considered to be 
a prominent risk factor for the development of HCC (Bartosch et al 2009, Levrero 2006, 
Wurmbach et al 2007). More than 170 million people (>4 million in USA alone) are 
infected and HCV-related liver disease is increasing globally. Although a strong 
relationship between HCV-induced chronic liver disease and development of HCC is 
widely accepted, the molecular mechanism of HCV-induced hepatocarcinogenesis is not 
clearly understood.   
 
HCV is a positive strand RNA virus classified as a hepacivirus of the family 
Flaviviridae (Moradpour et al 2007, Poenisch and Bartenschlager 2010). Among the 6 
genotypes, 12 subtypes and various quasispecies (Mellor et al 1995), 1a and 1b are the 
most prevalent strains in the US and are least responsive to the currently available 
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antiviral treatments (Fried et al 2002, Manns et al 2001).  HCV genome (9600 nt) 
encodes a single polyprotein that is processed co-translationally into three structural (C, 
E1 and E2) and seven nonstructural (NS) polypeptides (p7-NS2-NS3-NS4A-NS4B-
NS5A-NS5B) (Lindenbach and Rice 2005). Similar to other positive strand RNA viruses, 
HCV replicates via synthesis of negative strand RNA using replication complexes (RCs) 
comprising most of the NS proteins and yet undefined cellular factors (Bartenschlager et 
al 2010, Poenisch and Bartenschlager 2010).  The virus employs a remarkable survival 
approach by recruiting an abundant liver-specific miR-122 for stability and replication of 
its genomic RNA (Jopling et al 2005, Machlin et al 2011). During infection, HCV 
induces web-like membranous structures, and uses lipid-raft and microtubule filaments 
(MTFs) for its replication and transport (Lai et al 2008, Moradpour et al 2007, Wolk et al 
2008). Additionally, the viral NS3/4A protein cleaves retinoid inducible gene-1 (RIG-1) 
and mitochondrial antiviral signaling protein (MAVS) to suppress innate immunity (Gale 
and Foy 2005, Qu and Lemon 2010, Raychoudhuri et al 2010). It also induces ER stress 
and alters a cascade of signal transduction pathways that control cell cycle and cellular 
growth and metabolism (Fukasawa 2010, Tardif et al 2005, Waris et al 2002b).  
 
HCV-induced molecular alterations in infected cells significantly contribute to 
HCC development and progression.  These alterations may include: i) loss of tumor 
suppressor proteins; ii) activation of oncoproteins such as c-Myc; iii) activation and 
secretion of cytokines such as transforming growth factor TGF-β; and iv) alterations in 
the Wnt/ß-catenin signaling leading to nuclear accumulation of β-catenin, which are 
found in 33 to 67% of HCC cases (Bartosch et al 2009, Park et al 2009).  Activation of β-
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catenin is essential for liver development because deletion of the protein in mice results in 
fetal death due to impaired liver cell proliferation and increased apoptosis (Thompson 
and Monga 2007). The activated β-catenin has been demonstrated in cells located at the 
tumor’s invasive front in colon carcinomas (Zulehner et al 2010). The Wnt/ -catenin 
signaling pathway is also important for tumor progression because it modulates 
differentiation and maintenance of stem cells (Alison 2005, Lee et al 2006a, Zulehner et 
al 2010).  
 
CSCs display several key characteristics of normal tissue stem cells such as self-
renewal and unlimited proliferative and differentiation capacity.  They also possess the 
intrinsic ability to reproduce all aspects of the parent tumor after metastasis (Alison 
2005).  Thus, the “hierarchical model of cancer” considers CSCs as tumor “seed 
elements”, which are responsible for cancer initiation, re-initiation after metastasis and 
local recurrence after therapy (Marquardt et al 2010, Shi et al 2008).  Histopathology 
study of chronic liver disease and experiments in mice support the existence of CSCs in 
HCC (Mishra et al 2009, Shi et al 2008).  The origin of CSCs and factors affecting their 
fate are still being debated.  Recent studies indicate that induction of “stemness” in 
normal tissues or abnormal self-renewal, differentiation and proliferation of 
stem/progenitor cells might be key elements in the generation of CSCs (Lowry et al 2008, 
Mishra et al 2009).  
  
Multiple transcription factors and signaling pathways, including Wnt/ß catenin, 
Notch and Hedgehog, may be involved in the induction and maintenance of “stemness” 
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in fully differentiated cells (Thompson and Monga 2007, Yin et al 2010). Induction of 
pluripotency/multipotency in adult somatic cells can be carried out by simultaneous 
expression of several transcription factors (a set of Oct4, Sox2, Klf4 and c-Myc or Oct4, 
Sox2, Lin28 and Nanog) in recipient adult cells using various delivery vehicles such as 
viruses, transposons, and bacterial plasmids (Aoi et al 2008, Kaji et al 2009, Park et al 
2008).  Successful generation of pluripotent stem cells (iPSCs) has been accomplished by 
manipulating culture conditions and with limited number of pluripotency factors (Kim et 
al 2009). The most widely accepted evidence for pluripotency/multipotency is the 
formation of spheroids and teratoma, and unlimited self-renewal of the reprogrammed 
cells. 
 
 Because HCV replicates in fetal hepatocytes and the presence of CSCs have been 
demonstrated in HCC (Alison 2005, Lazaro et al 2007, Mishra et al 2009), It was 
essential to investigate whether HCV could induce cancer stem cell-like properties in 
liver-derived cells. This study shows that continued HCV expression is linked to the 
overexpression of a putative stem cell marker DCAMKL-1 that is used by the replicon 
for its efficient replication. Using various cell lines and a tumor xenograft model, the 
study further demonstrate that majority of HCV replicon-expressing cells acquire 
characteristic of hepatic progenitor cells, and form a distinct tumor phenotype than the 
parent cells lacking the replicon. The HCV-related tumors possess CSCs with higher 




2.   Materials and Methods 
 
2.1.  Antibodies  
  
Antibodies used in this study were purchased as indicated and used in accordance 
with the manufacturer’s suggestion:  anti- DCAMKL-1, CD133, SOX2, LGR5, CK19, 
human serum albumin, α-fetoprotein and HCV NS5B polymerase were purchased from 
Abcam;  anti- α-tubulin, Lin28B, c-Src,  and actin ( Cell Signaling); anti-c-Myc and anti- 
Oct3/4 (Santa Cruz Biotechnologies);  anti-Lin28 (Protein Tech Group), and anti-Klf4 
(Abgent).  
 
2.2.  Cell culture and transfection assay 
 
The FCA4 cells are derived from Huh7 hepatoma cell line and replication of a 
subgenomic HCV replicon in this cell line has been characterized previously (Ali et al 
2002, Guo et al 2001). The GS5 cells are derived from Huh7.5 cell line [interferon cured-
Huh7 cells negative for the HCV replicon (Blight et al 2002)] and express HCV 
subgenomic replicon that encodes NS5A-GFP (Nelson and Tang 2006). These cell lines 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 1x 
Pen/Strep, 1x non-essential amino acids and 10% fetal bovine serum (all from 
Invitrogen), and maintained at 37°C and 5% CO2. To evaluate effects of microtubule 
disruption on HCV replication, Huh7.5 and GS5 cells (each ~ 1x106) were treated with 
vinblastine (30 µM) or DMSO (vehicle) for 3, 6, 9, 12 and 24 h.  Total lysates of cells 
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were prepared according to the protocol described for Pierce Cell Lysis Kit for Western 
blot (M-PER). 
 
The siRNA that targets nt 308-327 (5’GGGAGTGAGAACAATCTAC3’) of both 
AS and AL isoforms of DCAMKL-1 mRNAs (siDCAMKL-1) and scrambled siRNA 
(SCR) were purchased from Ambion.  Incremental amounts of the siDCAMKL-1 or SCR 
RNAs (0, 20, 50, 100 nM) were transfected into GS5 cells using SiPORT NeoFX 
transfection agent (Applied Biosystems) according to the manufacturer’s protocol.  
Similar amounts of transfection reagent alone were used in control transfection. The cells 
were harvested 48 hr post-transfection to analyze RNA and protein levels.   
 
2.3.  Florescence-activated cell sorting (FACS)  
  
The DCAMKL-1 antibodies were conjugated with Dylight 549 (Thermo Fisher) 
using Pierce kit. The conjugated DCAMKL-1 antibodies were purified and allowed to 
bind cell surface DCAMKL-1 of Huh7.5 or GS5 cells for 30 minutes at RT as described 
(May et al 2008, May et al 2010). The cells were washed twice with autoMACS rinsing 
buffer (Miltenyi Biotec), resuspended in the same buffer and sorted using Influx-V Cell 
Sorter (Cytopeia, Seattle).  The instrument was calibrated with unstained cells. The 
DCAMKL-1-positive and negative cells were collected separately in DMEM and grown 
as described above. For spheroid assay, 100 DCAMKL+ or DCAMKL- cells in 2X 
DMEM media (50 ul) were mixed with matrigel (50 ul) on ice-bath, plated in non-
adherent/ultralow attachment 96-well plates (BD Biosciences, CA). Fifty microliter 
media was added on the top of the gel 2 hr later and the cells were grown as described 
 
45 
above. Two weeks later, 100 ul DMEM were added in each well. The spheroids were 
evaluated and photographed under inverted light microscope after 4-5 weeks.   
 
 2.4. Real-time reverse transcription-PCR analyses 
 
 Total RNAs were isolated from culture cells or tumor xenografts using RNeasy 
isolation kit (Qiagen).  The RNA samples were subjected to reverse transcription with 
Superscript II and random hexanucleotide primers (Invitrogen). In the subsequent step, 
the cDNAs were used as templates to perform real-time PCR by SYBR chemistry method 
(SYBR® Green I; Molecular Probes).  The target (HCV and DCAMKL-1) and control 
(actin) RNAs were amplified using Jumpstart Taq DNA polymerase (Sigma) and the 
following primers: 
Actin: 5’GGTGATCCACATCTGCTGGAA-3’(forward) 
and 5’ATCATTGCTCCTCCTCAGGG3’ (reverse);  
DCAMKL-1: 5’AGTCTTCCGATTCCGAGTTGAG3’ (forward);  
and  5’CAGCAACCAGGAATGTATTGGA3’ (reverse);  
HCV: 5’CGGGAGAGCCATAGTGG3’ (forward)  
and 5’AGTACCACAAGGCCTTTCG3’ (reverse).  
The crossing threshold values assessed by the real-time PCR were evaluated for 
the transcripts and normalized with β-actin mRNA. The mRNA levels were expressed as 
fold change relative to control with ± SEM value. 
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2.5. Tumor Xenografts in mouse model 
  
Athymic nude Balb/c mice were purchased from Jackson Laboratory and housed 
in pathogen-free conditions. The animals were treated in accordance with guidelines of 
the American Association for Accreditation of Laboratory Animal Care and the Policy on 
Human Care and Use of Laboratory Animals.  The studies reported here were pre-
approved and supervised by the Institutional Animal Care and Use Committee (IACUC). 
Huh7.5 or GS5 cells (5 × 106) were washed with PBS three times, resuspended in the 
same buffer, and injected subcutaneously into the dorsal flanks of 4–6 week old mice (3 
mice for each injection). Tumors were measured with calipers and the volumes were 
calculated using formula: 0.5 X (length X width2). The tumors were resected 4-6 weeks 
after cell transplantation and the portions of the tumors were preserved in 5% formalin 
for immunohistochemistry and stored at -800 C in RNase inhibitors for real-time PCR or 
directly frozen for Western Blot analyses.  The control animals were treated similarly but 
injected with same volume of the buffer. 
 
2.6.  Immunohistochemistry  
 
Heat-induced epitope retrieval was performed on 4 µm formalin-fixed paraffin-
embedded sections using a pressurized Decloaking Chamber (Biocare Medical) in citrate 
buffer (pH6.0) at 99°C for 18 min.  Slides were sequentially treated with 3% hydrogen 
peroxide, normal serum and BSA at room temperature for 20 min. After incubation with 
primary antibodies and washing with PBS, the slides were incubated in peroxidase-
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conjugated EnVision™+polymer detection kit (DAKO). Slides were developed with 
diaminobenzidine (Sigma). 
 
2.7.  Immunofluorescence and confocal microscopy 
 
Cells grown on glass cover-slips (VWR) were rinsed briefly in phosphate-
buffered saline (PBS), fixed in 4% paraformaldehyde in PBS pH 7.4 for 20 min at room 
temperature, washed twice with ice cold PBS and permeabilized in ice-cold acetone. 
Cells were incubated with blocking buffer (10% serum, 0.01 % Triton X-100, in PBS, pH 
7.4) for 1 hour, washed with PBS and treated with primary antibodies in PBS-T 
containing 1% BSA for 1-2 hr at room temperature or overnight at 4°C.  After thorough 
washing with PBS-T, cover-slips were incubated in appropriate AlexaFluor conjugated 
secondary antibodies.  The nuclei were counterstained with DAPI (0.1-1 µg/ml PBS).  
The cover-slips were mounted on microscope slides in ProLong Gold antifade reagent 
(Invitrogen) for detection of Immunofluorescence using Nikon 80i or Leica TCS NT (for 
confocal microscopy). 
 
2.8.  DCAMKL-1 staining in human liver tissue array  
  
The liver tissue arrays were purchased from US Biomax (Rockville, MD).  The 
array contains 30 normal and cancer adjacent normal liver tissues, 10 cases of 
inflammation with HBV, 9 samples of cirrhosis with HBV, and 31 samples of cirrhosis 
without HBV infection.  The arrays were subjected to immunohistochemical staining as 
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described above using anti-DCAMKL-1 antibodies (ab31704).  The intensity of 
DCAMKL-1 were evaluated and plotted on the arbitrary scale of 0-3.  
 
2.9.  Induction of human iPS cells  
 
The minicircle producer plasmid pMC.BESPX and the E.coli strain 
ZYCY10P3S2T were obtained from Dr. Zhi-Ying Chen, Stanford University School of 
Medicine. The  ZYCY10P3S2T strain was transformed with pMC.BESPX and grown in 
5 ml LB containing Kanamycin (50 ug/ml) at 37°C with shaking at 250 rpm. An 
overnight culture were grown by combining 100-ul of the previous culture with 400 ml of 
terrific broth (TB) containing Kanamycin (50 ug/ml). On day 2 after 16-18 hours (OD600 
reading between 4-5), the minicircle induction mix (400 ml LB, 16 ml 1N NaoH and 400 
ul 20% L-arabinose) was combined with the overnight culture and incubated at 32 °C 
with shaking at 250 rpm for 5 hours. Bacteria were then pelleted and minicircle isolated 
using Qiagen kit according to manufacturer’s protocol with some modifications (double 
volumes of P1, P2, and P3 buffers were used.  After purification, just the reprogramming 
cassette is obtained and bacterial elements were removed.   
 
3.   Results 
 
Hepatoma cells harboring HCV replicon express multitude of stem cell-related 
proteins and exhibit cancer stem cell-like features.  Normal adult hepatocytes are fully 
differentiated cells and lack expression of stem cell markers and pluripotency factors 
(Mishra et al 2009).  However, these cells can be induced to proliferate rapidly after 
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partial hepatectomy and can also be reprogrammed into pluripotent cells (Aoi et al 2008).  
In This study we investigated the impact of HCV on partial reprogramming or 
retrodifferentiation of GS5 cells that are derived from a hepatoma cell line (Huh7.5).  
These cells harbor a Geneticin (G418)-selectable subgenomic HCV-1b replicon that 
encodes HCV nonstructural proteins NS3 through NS5B, and a functionally active 
NS5A-green fluorescent protein (GFP) chimera (Moradpour et al 2004, Nelson and Tang 
2006).  The cells partially mimic chronic HCV infection in tissue culture conditions due 
to sustained expression of the replicon in the presence of G418. The intensity of GFP in 
these cells can be used as a surrogate marker for the efficiency of the HCV RNA 
replication (Nelson and Tang 2006).  
 
By indirect immunofluorescence microscopy, extensive expression of several 
putative stem cell/pluripotency markers (CD133, DCAMKL-1, Lgr5, Sox2, Oct4, Lin28) 
and c-Myc oncogene was observed in the GS5 cells that also demonstrated high level of 
HCV replicon expression as evidenced by the presence of intense NS5A-GFP (see 
Fig.2.1 and Appendix 1).  Eccentric staining of DCAMKL-1 was noted in the area where 
punctate localization of the HCV replication complexes (RCs) was more intense.  
Previous studies have shown that HCV replication complexes associate with 
microtubules through NS5A and NS3 proteins and their saltatory movements are fully 
dependent on the intact microtubule filaments (Lai et al 2008, Wolk et al 2008).  Since 
DCAMKL-1 catalyzes polymerization of tubulins into microtubules (Kim et al 2003, Lin 
et al 2000), next to be investigated was the possible role(s) of DCAMKL-1 in HCV 
replication.  The Fig. 2.2A shows relative localization of the RCs (marked by punctate 
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GFP) and DCAMKL-1 in the context of microtubules in GS5 cells.  The cells with high 
HCV expression (indicated by double arrow) showed higher DCAMKL-1 abundance. 
Both DCAMKL-1 and the HCV RCs were concentrated in the regions showing intense 
staining for microtubule filaments.  In contrast, cells without high HCV expression 
showed much lower expression and localized staining of DCAMKL-1 (single arrow). 
These observations suggest a relationship between HCV replicon expression and 
DCAMKL-1 levels in a subset of GS5 cell line. 
 
 3.1.  DCAMKL-1-positive GS5 and Huh7.5 cells exhibit cancer stem cell-like      
 properties      
 
Recent studies from this laboratory (May et al 2008, May et al 2009, May et al 
2010) showed that DCAMKL-1-positive cells can be isolated from colon and pancreatic 
cancer cell lines using FACS method (May et al 2009), and that isolated DCAMKL-1-
positive cells formed spheroids in matrigel (BD Biosciences) and displayed CSCs 
properties. This established method was used in this study to isolate DCAMKL-1 and 
HCV NS5A-GFP double positive cells (HCV+DCAMKL-1+) from GS5 and DCAMKL-
1+ cells from Huh7.5 cell line. The FACS data presented in Fig. 2.2B (left panel) revealed 
relatively higher percentage of DCAMKL-1+ cells in GS5 pool (1.42%) than that of the 
Huh7.5 control (0.36%).  Both cell-types positive for DCAMKL-1 formed spheroids in 
matrigel (with approximately 5-10% efficiency) in 3-4 weeks (middle panel).  GS5-
spheroids demonstrated higher HCV NS5A-GFP expression in the budding areas than the 








Figure 2.1. Indirect immunoflorescence microscopy for visualization of cells 
coexpressing the HCV replicon (indicated by NS5A-GFP, green) and putative 






form spheroids under similar conditions. These results indicate that a subpopulation of 
GS5 cells co-expressing high levels of HCV replicons and DCAMKL-1 may exhibit 
CSCs features. 
 
3.2. Tumors initiated by GS5 cells are distinct from the Huh7.5-derived 
tumors in athymic nude mice 
  
Assuming that very high NS5A-GFP expressing cells also have high DCAMKL-1 
expression level (Fig. 2.2A), we used FACS to isolate the top 26% of total GS5 
population  with the highest green florescence intensities (Fig. 2.3A, indicated by R4). 
These cells were  then expanded in tissue culture and injected into the dorsal flanks of the 
nude mice.  In parallel, similar numbers of Huh7.5 cells were injected into the control 
mice.  Since both cell lines contain DCAMKL-1+ cells to varying extents, the 
transplanted cells formed tumors with 50-60% efficiency over a period of 3-4 weeks.   An 
example of GS5 tumor in one of the mice is shown in Fig. 2.3B (indicated by an arrow).  
The resected tumors (example shown in Fig. 2.3C) were phenotypically characterized and 
analyzed for the expression of stem cell/pluripotency markers by immunohistochemistry.  
A significant number of DCAMKL-1-positive cells were localized in certain areas of 
GS5-tumors in which most cells exhibited high level of activated c-Src expression, 
indicating that these tumors are highly aggressive and possess metastatic potential (Fig. 
3E). Only rare c-Src and DCAMKL-1 expressing cells were observed for the Huh7.5-





Figure 2.2. Correlation among DCAMKL-1, HCV and CSCs traits in the replicon-
expressing cells.  (A) Confocal microscopy for localization of HCV NS5A-GFP (green), 
DCAMKL-1 (red) and microtubules (magenta) in GS5 cells as indicated. The field shows 
two cells as an example; single and double arrows indicate low and high HCV replicon-
expressing cells respectively as indicated by the relative GFP intensities.  (B) Isolation of 
DCAMKL-1-positive cells from Huh7.5 and GS5 cells grown in tissue culture by FACS 
method (left panel), and Spheroid assay (right panel) using isolated DCAMKL-1+ 
(Huh7.5) or GFP+DCAMKL-1+ (GS5) cells. One hundred cells were plated with culture 
media containing 50% matrigel in a 96-well plate. The cells were grown in standard 









Figure 2.3. Characteristics of tumor xenografts developed by GS5 and Huh7.5 cells. (A) 
The highest GFP-expressing cells (R4 gated, 26% of total) were isolated by FACS 
method, expanded in tissue culture and 5 million cells were injected into the dorsal flank 
of a nude SCID mice (in duplicate). In control animals, similar numbers of Huh7.5 cells 
were transplanted.  (B) An example of GS5 tumor within animal (indicated with an 
arrow). (C) Resected tumor from the animal. The tumors developed by Huh7.5 (not 
shown) had varying size but usually smaller than that of GS5-tumors (not shown). Co-
staining of DCAMKL-1 and active c-Src in the tumor tissues of Huh7.5 (D) and GS5 (E) 
by immunohistochemical method. Purple, DCAMKL-1; Brown, activate c-Src [pTyr418 
c-Src].  (F) Control, section of the mouse (B) liver stained as in (D, E) showing that both 









2.3F).  This in vivo observation complements our preliminary finding that activated c-Src 
is highly expressed in GS5 cells grown in laboratory cell cultures. We next compared 
expression of a number of stem cell/pluripotency markers in the xenograft tumor tissues 
and culture cells which were derived from both the cell lines.  The total cell lysates (20-
30 ug) were subjected to Western blot analysis using specific antibodies against an array 
of stem cell-associated markers. 
 
As shown in Fig. 2.4A, the levels of DCAMKL-1, LGR5 and CD133 were 
considerably enhanced in GS5 cells as compared to the control cells (Huh7.5).  However, 
the levels of pluripotency factors (Oct4, Sox2 and Lin28) were similar in both cell-types.  
Unlike cultured cells, DCAMKL-1, LGR5 and CD133 expression and that of 
pluripotency factors (Lin28, Sox2, Oct4 and c-Myc) in both tumors were similar.  During 
GS5 cell transplantation, the animals did not receive the replicon selection marker (G418 
drug) due to its high cytotoxicity.  As a result, GS5-tumors lost the replicon expression 
over a 3-4 week period as indicated by the absence of NS5B band in the Western blot 
(Fig. 2.4B, control markers).  This is consistent with our observation that withdrawal of 
G418 from GS5 culture gradually diminishes the HCV expression (see Fig. 2.7, left 
panel).  These data suggest that despite the gradual HCV decline over a few weeks, 
initiated tumors continued to grow in the animals. 
 
Previous reports indicated that immature hepatic progenitor cells such as oval 
cells and cholangiocytes in liver express CK19 protein (Aoi et al 2008, Banaudha et al 
2010). The protein is also considered a marker for aggressive HCC subtypes. The CK19 
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expression in HCC (with or without HCV) correlates with the lower patient survival and 
higher rates of tumor recurrence (May et al 2010, Mellor et al 1995). Striking differences 
in CK19 expression were observed between the GS5 and Huh7.5 xenografts by 
immunohistochemistry (Fig. 2.5). Higher percentages of GS5-tumor cells expressed 
CK19 (Fig. 2.5B) whereas rare Huh7.5-tumor cells expressed this protein (Fig. 2.5A).  
This difference was confirmed by Western blot analysis using replicon-expressing two 
cell lines.  The total lysates prepared from cells grown in tissue culture revealed that both 
GS5 (Fig. 2.5C, left panel) and FCA4 (Fig. 2.5D) cells expressed much higher levels of 
CK19 than their parent cell-types (Huh7.5 and Huh7 cells respectively).  This trend was 
clearly reflected in the respective tumor xenografts derived from GS5 and Huh7.5 cells.     
 
To induce pluripotency in Human hepatoma cell line Huh7, the minicircle vector, 
p2phiC31-LGNSO was transfected into Huh7 cells.  In the minicircle DNA, the 
reprogramming cassette is driven by a CMV promoter leading to the expression of 
LIN28, GFP, NANONG, SOX2 and OCT4. The reprogramming genes coding regions in 
the cassette are linked by 2A protease sequence, so after transfection the expressed 
proteins undergo self cleavage by peptide 2A. In parallel, Huh7 cells were also 
transfected with BM45 plasmid harboring HCV replicon, controls were empty vector 
DNA transfected Huh7 and lipofectamine only. Total lysates analyzed on SDS-PAGE 
showed that both LSNGO and BM45 transfected cells (Fig. 2.6C, lanes 3 and 5 
respectively) expressed  higher levels of CK19 than their parent untransfected Huh7 cells, 








Figure 2.4. Relative expression of putative stem cell markers and induced pluripotency 
factors in the culture cells (A) and tumor tissues (B) as indicated. Western blot analysis 
was carried out with 20 ug of total lysates of the cells (left panel) and their respective 
tumors (right panel).  Protein bands of stem cell markers (DCAMKL-1, LGR5, and 
CD133) and induced-pluripotency (iPSCs) factors (Oct4, Sox2, c-Myc, Lin28) were 
detected by the specific antibodies as indicated. The viral NS5B polymerase and actin 
were used as controls. (C) Enhanced expression of DCAMKL-1 in an another HCV 













        
 
Figure 2.5. Unique features of the GS5-tumors. Enhanced expression of CK19 in GS5-
derived tumors (B) as compare to that of Huh7.5-derived tumors (A).  
Immunohistochemical staining (A, B) for CK19 (brown); Blue, nuclear stain.  (C) 
Western blot of total lysates (30 ug) of tumor xenografts (right panel ) or culture cells 
(left panel) of both cell lines probed for CK19. The upper band in the doublet is 
considered as full-length Ck19.  Actin, loading control. (D) Western blot for CK19 
expression in FCA4 cells that express a subgenomic HCV-1b replicon (indicated by the 







Lin28 was much more expressed by LSNGO transfected cells (Fig. 2.6 D lane 3) 
compared to control and mock cells (lanes 1 and 2 respectively).  
 
A similar strategy was employed to detect the hepatoblast marker, α-fetoprotein 
(AFP), in xenograft tumors and in tissue culture cells.  Western blot analyses reiterated 
immunohistochemical findings that GS5-tumor or GS5 culture cells expressed AFP at a 
much higher level than Huh7.5 controls (Figs 2.7 A, B, and C).  Lysates of GS5 tumors 
showed much higher relative expression pattern by Western blot than observed by 
immunostaining because AFP is secreted extracellularly (Fig. 2.7B vs. 7C, right panel). 
These observations suggest that GS5 cells although were originated from Huh7.5 cells, 
they maintain a distinct cellular phenotype in culture conditions as well as in tumor 
xenografts.  
 
We also observed a number of CK19+AFP+ and CK19+AFP- progenitor-like cells 
in the GS5 tumors (Appendix 2a), whereas these cells were rarely seen in the Huh7.5-
tumors (Appendix 2b).  The most likely inference of these observations could be that 
high level of chronic HCV replication results in retrodifferentiation of cells leading to 
acquisition of hepatic stem/progenitor-like characteristics. 
 
3.4.  HCV replication influences activation of ß-catenin   
 
Previous studies have shown that c-Myc and CK19 expression is affected by β-
catenin expression (Thompson and Monga 2007, Zulehner et al 2010).  The high level of 









Figure 2.6. HCV replicon and pluripotency factors induce CK19 overexpression in Huh7 
cells. (A) Schematic of the reprogramming cassette-expression plasmid. The CMV 
promoter-driven synthesis of a single mRNA results in the translation of a polyprotein  
that is self-cleaved by 2A peptide sequence into individual Lin28, GFP, Nanog, Sox2 and 
Oct4 proteins. (B) Schematic of preparation of ‘Minicircle’ from the vector DNA (A) for 
transfection into Huh7 cells. (C) Western blot after transfection of HCV subgenomic 
replicon (lane 5), Minicircle (LGNSO, lane 3), and empty vector DNA (lane 4). Lane 1, 
untransfected; lane 2, transfection with lipofectamine alone.  (D) Western blot showing 
much higher expression of Lin28 in LNGSO transfected cells (lane 3) than untransfected 
(lane 1) or Lipofectamine alone transfected Huh7 cells (lane 2). (E) Western blot for two 
different HCV replicon-expressing cell lines (GS5 and FCA4) in the presence (plus) or 
absence (minus) of G418 selection marker.  The specific bands of CK19, NS5B and actin 













Figure 2.7.  Expression pattern of hepatoblast marker in the tumor xenografts and parent 
culture cells.  Huh7.5-tumor (A) and GS5-tumor (B) were subjected to 
immunohistochemistry for staining of a-fetoprotein (AFP, brown). Blue, nuclear stain. 
(C) AFP expression in the total lysates (30 ug) of tumor xenografts (right panel ) or 













us to investigate the status of ß -catenin in response to the HCV replication.  The GS5 
cells cultured in the presence of G418 support continued high-level replication of the 
HCV RNA whereas withdrawal of G418 leads to decline in replicon expression as 
evidenced by decreased NS5B level in the cytoplasm (Fig.2.8A, left panel).  The NS5B 
reduction was accompanied by decline in both total and active nuclear ß-catenin (right 
panel). These results clearly suggest that continued HCV replication is required to 
maintain activation of the ß-catenin pathway in the absence of external Wnt ligands.  We 
also observed the presence of active ß -catenin in tumors as expected (Fig. 2.8B). 
However, there were no significant differences between the levels of active and total ß-
catenin in both tumor types, in consistence with the c-Myc expression profile for both 
tumors and cultured cells (Figs. 2.4A and 2.4B).  
 
3.5.  DCAMKL-1 is required for the HCV replication   
 
 HCV replication complexes associate with microtubule filaments (MTFs) and use 
the MTF-tracks for their movement and transport (Lai et al 2008, Roohvand et al 2009, 
Wolk et al 2008).  Since DCAMKL-1 protein is known to bind, stabilize and polymerize 
tubulins into MTFs (Lin et al 2000), we examined the effect of inhibiting DCAMKL-1 
expression on HCV replication. The GS5 cells were transfected with scrambled siRNA 
(SCR, control) or siRNA against DCAMKL-1 (siDCAMKL-1). This siRNA targets nt 
308-327 (the predicted site) in the DCAMKL-1 mRNAs encoding both the AL (long 




As shown in Fig. 2.9A, siDCAMKL-1 transfection in GS5 cells resulted in the 
inhibition (average 75% at 100 nM) of DCAMKL-1 mRNA level whereas the same 
concentration of the SCR had minimal effect.  The decrease in mRNA was accompanied 
by disappearance of the DCAMKL-1 protein in total lysates, suggesting that the siRNA 
had effectively inhibited DCAMKL-1 expression (Fig. 2.9B, lanes 3, 4).   The 
DCAMKL-1-depletion in these cells also resulted in significant reduction (70-80%) of 
both the HCV RNA and NS5B polymerase levels (Fig. 2.9A and 9B, lanes 3, 4).  This 
effect appears to be specific as the level of another pluripotency marker, Lin28B (Guo et 
al 2006), was unaffected by the siDCAMKL-1 treatment (Fig. 2.9B).  
 
The immunosuppressive drug cyclosporine A (CsA) is known to inhibit 
cyclophilins (CypA and CypB), which interact with crucial components of the HCV RCs 
such as NS5A and NS5B (Watashi et al 2005, Yang et al 2008).  CsA downregulates 
HCV replication by inhibiting activities of the RCs (Watashi et al 2005, Yang et al 2008).  
More often, however, CsA-treatment results in drug-resistance (Liu et al 2009, Puyang et 
al 2010).  The CsA treatment of GS5 cells effectively inhibited HCV replication (Fig. 
2.9C) and diminished level of NS5B in the GS5 lysates (Fig. 2.9D, lanes 3-5).  
Interestingly, CsA treatment resulted in a moderate increase in the DCAMKL-1 protein 
(Fig. 2.9D, lanes 3-5) without increasing its transcription level (Fig. 2.9C). It has been 
reported that CsA activates AKT and suppresses PTEN; both events culminate in the 




Figure 2.8. Activation of b-catenin in response to the HCV replication. (A) The 
cytoplasmic and nuclear lysates of GS5 cells cultured for 2 weeks in the presence (plus) 
or absence (minus) of G418 selection marker were subjected to Western blot using 
specific antibodies as indicated. The unphosphorylated form of ß-catenin is shown as 
active protein.  (B)  Total lysates prepared from tumor xenografts were analyzed by 





The activation of AKT/mTOR signaling favors enhanced cap-dependent protein 
synthesis and cell survival. These observations imply that even though CsA successfully 
inhibits HCV replication during early phase of treatment, enhanced DCAMKL-1 level 
may eventually contribute to CsA-resistance. In fact, we noticed a certain level of NS5B 
was not affected by the sequential increase in CsA concentrations (1 through 6 ug/ml, 
Fig. 2.9D, lanes 3-5).  
 
3.6.  HCV incites resistance to MTFs disruption  
  
The anti-neoplastic drug, vinblastine, binds α-tubulin and inhibits microtubule 
assembly by preventing addition of new tubulin subunits (Rendine et al 2010).  We 
evaluated the effect of vinblastine on Huh7.5 and GS5 cells at different time-points. As 
shown in Fig. 2.10 B (lower panel), vinblastine treatment caused clear disruption of 
MTFs architecture and showed bundling of MTFs within 7 hr in Huh7.5 cells. Most GS5 
cells showed similar bundling pattern and inhibition of NS5A-GFP expression.  
However, the bundling of MTFs was less evident in cells showing high NS5A-GFP 
presence (Fig. 2.10 A, indicated with an arrow).  Longer treatment and further kinetic 
analysis suggested that nearly all the GS5 cells eventually died within a week.  During 
MTF bundling, we further noticed that DCAMKL-1 staining in GS5 cells was weak and 
the protein appears to be dislodged from the MTF bundles. Control cells treated with 
DMSO alone did not show MTF disruption. These results reiterate the study overall 






Figure 2.9.  DCAMKL-1 is required for the HCV replication. (A) siRNA against 
DCAMKL-1 (siDCAMKL-1, 50 nM and 100 nM) or scrambled siRNA (SCR, 100 nM) 
were transfected into GS5 cells in triplicate.  Total RNAs were extracted and subjected to 
real-time RT-PCR.  The levels of HCV and DCAMKL-1 RNAs were considered one in 
untransfected GS5 cells (Cont.).  Actin mRNA in each sample was used as internal 
control for PCR.  (B)  Western blot analysis of siRNAs transfected (lanes 2-4) and 
untransfected (lane 1) samples as indicated.  (C) Real-time PCR was performed for 
detection of HCV and DCAMKL-1 RNA levels after treatment with CsA (3 ug/ml).  
Control, DMSO vehicle.  (D) Effect of CsA on the levels of HCV NS5B polymerase and 
DCAMKL-1.  The GS5 cells were treated with 1, 3, 6 ug/ml CsA (lanes 3-5).  Lanes 1 
and 2 represent untreated and DMSO (vehicle) treated samples respectively. Actin, 







4.   Discussion 
 
We have used a proven replicon-based system to study long-term effects of HCV-
1 on cells, as a chronic infectious model for HCV-1 is not available.  We investigated 
HCV-induced phenotypic alterations in liver-derived GS5 cells that express a 
subgenomic replicon encoding NS3 through NS5B of the HCV genome.  The C-terminus 
GFP tagged NS5A (NS5A-GFP) expressed from the replicon is efficiently incorporated 
into active replication complexes (RCs) and is distributed in a punctuate pattern in the 
cytoplasm with higher concentrations localized in the perinuclear regions  [Figs. 2.1 and 
2.2 (Gosert et al 2003, Moradpour et al 2007, Poenisch and Bartenschlager 2010)].  GFP 
intensity correlates with the level of HCV replication in these cells. We demonstrated that 
a small subpopulation of intensely bright GFP+ cells contain RCs in the area highly 
enriched in DCAMKL-1 and microtubule filaments (MTFs).     
 
In some cases, co-localization of RCs, DCAMKL-1 and MTFs was observed by 
confocal microscopy.  These observations and subsequent analyses presented in Figs. 2.2, 
2.3 and 2.8 support the existence of an HCV-(DCAMKL-1)-MTFs-CSCs axis in GS5 
cells. Using both in vitro and in vivo models, our data provided evidence that this 
collaboration promotes HCV replication and HCV-induced hepatocarcinogenesis. We 
further found that HCV replication results in the induction of putative stem cells/CSCs 
markers and activation of ß-catenin, which are required for the maintenance and self-









Figure 2.10. Effects of vinblastin on microtubule filaments and HCV expression. Huh7.5 
(B) or GS5 (A) cells were treated with vinblastin (30 uM) for 7 hrs and subjected to 
indirect immunoflorescence microscopy using antibodies against α-tubulin. Arrow, a 













stem/progenitor cells (Lee et al 2009, Zhang et al 2008, Zulehner et al 2010). The 
stem/progenitor cells in an adult organ such as liver are considered to be: i) ‘privileged 
cells’ in their niches; ii) relatively resistant to apoptosis, and iii) possess longer life-span 
than fully differentiated cells. Thus, HCV appears to employ a unique strategy to ensure 
its long-term survival in the infected cells simply by directing the cells to exhibit stem 
cell-like properties.  
 
 Our studies suggest a novel role of DCAMKL-1 in the HCV replication. Higher 
expression of DCAMKL-1 in hepatic cells, and its association with MTFs, led to higher 
levels of HCV replication suggesting a certain advantage for virus replication.  MTFs 
represent dynamic, polarized polymers of α- and ß-tubulin heterodimers that undergo 
phasic polymerization and depolymerization required for cellular transport and cell 
division (Roohvand et al 2009). DCAMKL-1, by virtue of its MTFs polymerizing and 
stabilizing activity may provide MT-dependent transport and fast, saltatory movements of 
RCs over long distances (Fukasawa 2010, Gale and Foy 2005). By promoting RC 
movement, DCAMKL-1 is likely to increase HCV replication efficiency. It may also 
compensate for architectural distortion created by HCV-induced membranous web-like 
structures in the cells. Roohwand et al. (Roohvand et al 2009) demonstrated that MTFs 
dynamic polymerization/depolymerization also affects post-fusion steps of the HCV life 
cycle, and that HCV core protein interacts with tubulin thereby enhancing microtubule 
polymerization.  The effects of viral proteins on DCAMKL-1 activities and the 
DCAMKL1 interaction with viral components are yet to be investigated.  
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Previous studies done by this lab revealed that DCAMKL-1 level is increased 
significantly in pancreatic and colon cancers and its knockdown causes marked reduction 
in tumor size in a xenograft model (May et al 2009, Roohvand et al 2009). In this study, 
we found evidence of higher DCAMKL-1 expression in human patients with liver 
cirrhosis than the normal liver tissues (Appendix. B). The cause of DCAMKL-1 
overexpression in tumors and its effects on CSCs is not known yet. Our studies presented 
here provide HCV as one causative agent for the overexpression of DCAMKL-1. The 
DCAMKL-1+ cells from both cell lines (GS5 and Huh7.5 cells) behave like CSCs in 
matrigel further reiterating the previous findings.  Therefore, HCV-led induction of 
DCAMKL1 in conjunction with enhanced expression of CD133, Lgr5, c-Myc and ß-
catenin may directly force the infected cells on the path of developing into CSCs.  
However, not all patients living with HCV develop HCC. Studies have shown that HCV 
NS5A inhibits apoptosis in infected cells by inhibiting oxidative stress-induced p38 
MAPK activation and K+ efflux (Raychoudhuri et al 2010).  Similarly, NS3/4A has been 
shown to promote hepatocyte survival and liver regeneration by enhancing NFκB 
activities and hepatoprotective TNFα (Rendine et al 2010). Thus, other factors may also 
play important role during HCV-induced hepatocarcinogenesis.  
 
Similar to many solid tumor cell lines, the hepatoma cells used in these studies are 
expected to contain a population of CSCs because of the expression of many putative 
stem cell and pluripotency markers (Nakanishi et al 2010). As a result, both GS5 and 
Huh7.5 cells were able to form solid tumors in athymic nude mice. We also observed that 
both tumors expressed human albumin suggesting that the tumors were derived from the 
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transplanted cells and contain mature human hepatocytes.  According to the ‘hierarchical 
model’ of cancer, the original phenotypes of CSCs represented in culture pool must also 
be maintained in their respective tumors due to self-renewal. We validated this 
assumption by comparing expression of hepatoblast and hepatic progenitor markers in 
culture cells and the tumor xenografts.  Each tumor, indeed, reflected the original 
phenotype of the parent culture cells.  For example, GS5 cells and its tumor xenografts 
exhibited much higher expression of CK19 and AFP than that of Huh7.5 controls by 
Western blot. The GS5-tumors also showed a very high population of CK19+AFP- 
(hepatic stem cells), CK19+AFP+ [hepatoblast and transit amplifying cells, ref. (Zhang et 
al 2008)].  These HCV-induced stem-like features were clearly absent in Huh7.5 culture 
cells and its tumor xenografts. Higher expression of CK19 in an another HCV replicon 
expressing cell line (FCA4) than the parent cell line (Huh7) suggests that these properties 
are not limited to GS5 cells. The detection of CK19+ oval cells in HCV-positive liver 
cirrhosis (Sun et al 2006) and co-expression of CK19 and AFP in hepatic progenitor cells 
(Zhao et al 2009) further support our observations. The HCV-induced distinct traits in 
culture cells were subsequently maintained in the GS5-tumor tissues even though the 
viral gene expression was diminished during later stage of the tumor development. 
 
Tsamandas et al. (Tsamandas et al 2006) demonstrated that hepatic progenitor 
cells (HPC) are frequently present in liver tissues of hepatitis C patients and their number 
tends to increase as the disease advances to cirrhosis which is a known risk factor for the 
HCC initiation. It was further demonstrated that a large group of patients that do not 
respond to the standard HCV treatment show higher expression of CK19 and AFP than 
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the responders and these proteins can be used as reliable markers for detecting the HPCs 
in these patients. Using extensive gene expression profiling of HCC tissues, other 
investigators independently reached to the conclusion that HCC originating from HPC or 
HPC-like cells express high level of CK19, AFP and certain stem cell signatures (Lee et 
al 2006b, Woo et al 2010). While supporting these observations, our in vitro and in vivo 
analyses further provide mechanistic insights that high expression and/or coexpression of 
CK19 and AFP is, indeed, caused by HCV-induced retrodifferentiation of hepatic cells 
leading to acquisition of HPC-like phenotype. These characteristics were universally 
detected in different cell lines and tumor model used here (GS5 and FCA4 cell lines, 
G418-withdrawl assay, and tumor xenografts). Our studies also revealed that multiple 
DCAMKL-1 positive cells were embedded in the areas of active c-Src expression in GS5 
tumors (Fig. 2.3E).  It is known that c-Src expression and activities are enhanced under 
varying stress conditions that favor tumor growth and metastasis (Allam and Ali 2010).  
In these aspects, the GS5-tumor traits are reminiscent of HCC with stem cell features 
(Ding et al 2004, Lee et al 2006b). Thus, it is conceivable that HCV-induced 
reprogramming of liver cells may contribute to both survival of the virus and 
hepatocarcinogenesis.  
 
Finally, our studies provide evidence that active ß-catenin accumulates in the 
nucleus in response to HCV expression which may explain higher-level c-Myc 
expression in GS5 than the controls [also see ref. (Milward et al 2010)]. Active ß-catenin 
was also detected in the tumor xenografts. Using human HCC tissue array and murine 
liver tumor model, Zulehner et al. (Zulehner et al 2010) demonstrated significant 
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correlation between CK19 expression and that of nuclear ß-catenin.  It has been further 
shown that lack of nuclear β-catenin causes cells to differentiate into mature hepatocytes 
whereas its presence induced retrodifferentiation into immature hepatocyte progenitors. 
Therefore, our data, in conjunction with published reports, support the concept of HCV-
induced reprogramming of the liver-derived cells.  Since the replicon used here lacks 
NS2 and C, E1 and E2 structural proteins, the impact of these proteins on the ‘cellular 
renovation and reprogramming’ by the virus could not be investigated. A long-term, 
chronic HCV infection model that produces high titer HCV particles such as improved 
version of JFH1 strain-based cell culture (Banaudha et al 2010, Wakita et al 2005) in 
normal human hepatocytes will likely to provide additional clues on these aspects. 
 
Although both Huh7.5 and GS5 or Huh7 and FCA4 cells originated from the 
same cell line and propagated under similar culture conditions, the long-term HCV 
expression (reminiscent to chronic infection) resulted in stable phenotypic changes in 
GS5 cells.  These acquired alterations were reproduced in the tumor xenografts of GS5, 
which conforms the hierarchical model of tumor initiation by CSCs.  Thus, it is highly 
likely that GS5 pool contains CSCs with features of hepatic stem cells or hepatic/biliary 
precursors because of retrodifferentiation and acquisition of stem cell/CSCs and 
oncogenic traits (see model proposed in Fig. 2.11).  Consequently, the HCV infection per 
se including HCV-induced HCCs poses increased threat of resistance to anti-viral and 
anti-cancer regimens, recurrence of the infection and/or tumors, and high mortality of 
patients (Frank et al 2010, Kieffer et al 2010a).  The Huh7.5 cells, on the other hand, 
retained their HCC phenotype both in culture and in tumor xenografts as it lacks the 
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HCV-induced alterations.  In conclusion, our data provides DCAMKL-1 as a novel 
cellular target for combating HCV replication and/or hepatic CSCs. To inhibit, 
DCAMKL-1 expression, siDCAMKL-1 (Fig. 2.9) can be delivered to the target cells 
using gene therapy approach by constructing an expression vector for the siRNA. 
Alternatively, this laboratory has tried delivery of the siDCAMKL-1 using nontoxic 
biodegradable nanoparticles (NPs) made of poly(lactide-co-glycolide) [PLGA].  The 
successful delivery of siDCAMKL-1 NPs at the site of tumors in mouse xenograt model 
led to the reduction in liver and pancreatic tumor size (Suraben et. el 2009).       In 
addition, our studies further argue comprehensive evaluations of anti-HCV drugs in the 
setting of chronic/long-term infection for their efficacies. 
 
5.   Chapter summary 
 
Hepatitis C virus (HCV) infection is a prominent risk factor for the development 
of hepatocellular carcinoma (HCC). Similar to most solid tumors, HCCs are believed to 
contain poorly differentiated cancer stem-like cells (CSCs) that initiate tumorigenesis and 
confer resistance to chemotherapy. This dissertation studies demonstrate that expression 
of HCV subgenomic replicon in cultured cells results in acquisition of CSCs traits.  These 
traits include enhanced expression of DCAMKL-1, Lgr5, CD133 and c-Myc in 
conjunction with long-term maintenance of pluripotency factors. The studies also show 
that HCV replication is severely impaired by siRNA-led depletion of the microtubule-
associated putative stem cell marker, DCAMKL-1. The DCAMKL-1-positive cells 
isolated by fluorescence activated cell-sorting (FACS) form spheroids in matrigel. The 
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work further demonstrates that HCV replicon-expressing cells initiate tumors in mice. 
The resulting tumors exhibit characteristics of HCCs that are originated from hepatic 
progenitor-like cells and are phenotypically distinct from the tumors initiated by parent 
cells lacking the replicon.  This phenotype expresses high-levels of α-fetoprotein, 
cytokeratin-19 and pluripotency markers.  HCV-induced activation of ß-catenin, c-Myc, 
and c-Src indicates the aggressive nature of the tumor. These results collectively suggest 
that HCV exhibits intrinsic ability to induce retrodifferentiation and CSC signatures, and 
















Figure 2.11. Proposed retrodifferentiation model for the HCV-induced liver 
carcinogenesis.  Solid arrows, pathways of normal hepatic stem cell differentiation; 
arrows with broken lines, possible source of Huh7.5- and GS5-derived tumors. Majority 
of Huh7.5 culture/tumor cells lack hepatic/biliary precursor markers although these cells 
contain stem/progenitor cell traits.  Therefore, they represent intermediate or 
differentiated hepatocytes.  On the other hand, GS5 culture/tumor cells contain stem 
cell/progenitor cell markers, and high population of CK19+AFP- (hepatic stem cells) and 
CK19+AFP+ (hepatoblast, transit amplifying cells or hepatic/billiary precursors).   The 
expression level of CK19 and AFP in these cells are remarkably higher than those of 
Huh7.5.  These acquired distinctions are likely attributed to retrodifferentiation of the 
parent Huh7.5 cells into GS5 phenotype that was induced by sustained expression of the 
HCV replicon. HPC, hepatic progenitor cell. (B) Probable consequences of the HCV-















A number of drugs that include the specifically targeted antiviral therapies for 
hepatitis C (STAT-Cs), and cellular targets against HCV (CTACs) are at various stages 
of clinical trials or have been stopped because of their adverse effects, multiple drug 
resistance or ineffectiveness in the patients (Kieffer et al 2010b).  The most successful 
among STAT-Cs include drugs against NS3 protease/helicase (telaprevir, boceprevir), 
NS5B polymerase (nucleoside and non-nucleoside analogues) and NS5A protein (BMS-
790052). The use of telaprevir or boceprevir, in combination with Peg-IFN/RBV regimen 
was reported to increase the SVR rate by 20% in shorter duration (within 24 weeks) as 
compared the SOC alone (48 weeks) in patients infected with HCV genotype 1.  
Similarly, impressive potency of NS5A inhibitor (BMS-790052) has been shown in 
clinical trial (Gao et al 2010).  With all these successful stories and enthusiasm, cure for 
the HCV infection has been elusive not only because of adverse effects on patients but 
also due to emergence of drug-resistance (Fridell et al 2010, Kieffer et al 2010b, Liu et al 
2009, Pockros 2010). Anemia (up to 37% with telaprevir and up to 56% with boceprevir), 
skin problems for telaprevir (rash and pruritis) and dysgeusia for boceprevir in addition to 
the influenza-like symptoms, cytopenias and depression are additional hindrance for a 
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successful treatment.  The viral variants with reduced susceptibility to STAT-Cs occur 
naturally at low levels due to error-prone HCV replication mechanism, and can be 
selected in patients not responding to STAT-C/SOC treatment. Susceptibility of HCV 
against these drugs diminishes due to gradual incorporation of mutations in the virus that 
have been demonstrated during in vitro and in vivo testing.  These drugs have huge 
potential for misuse due to prescribing physician’s poor understanding of the therapeutic 
populations, inadequate viral-assay testing, poor side-effect management, and lack of 
monitoring for antiviral resistance.  
 
Clinical trial by our group (Bader et al 2008) and subsequent studies by others 
(Harrison et al 2010, Milazzo and Antinori 2010, Milazzo et al 2010) suggest that certain 
statins (fluvastatin, simvastatin, lovastatin, and mevastatin) but not pravastatin  show 
anti-HCV activities both in experimental models and in patients with hepatitis C.  It has 
been demonstrated that the FDA-approved doses of fluvastatin are well tolerated by 
patients with HCV and the drug can provide aid standard of care therapy (Delang et al 
2009). Statins are inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG CoA) 
reductase, which is a rate-limiting enzyme in cholesterol biosynthesis that catalyzes the 
conversion of HMG-CoA to mevalonic acid (Fig. 3.1).  These drugs are used for the 
treatment of hypercholesterolemia and have been reported to exhibit antiviral activities 
against a number of viruses (Gilbert et al 2005).  The precise mechanism of the anti-HCV 
activity of statins has not yet been defined. Recent studies suggest that the anti-HCV 
activity of statins may result from inhibition of geranylgeranylation of cellular proteins 
rather than the inhibition of cholesterol synthesis.  Geranylgeranylation is a 
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posttranslational modification that covalently attaches geranylgeranyl to various cellular 
proteins to facilitate their membrane association. These geranylgeranyl groups are 
isoprenoids synthesized in the cholesterol biosynthesis pathway. The HCV genome does 
not code a geranylgeranyl protein suggesting that the replication of the HCV needs the 
host cell geranylgeranyl pyrophosphate synthesis. More recently, FBL2 has been reported 
to be a host target for geranylgeranylation. Geranylgeranylation of FBL2 appears to be 
critical for HCV replication because the association between FBL2 and NS5A, an 
interaction that is a prerequisite for HCV replication, depends on geranylgeranylation of 
FBL2 (Kapadia and Chisari 2005, Wang et al 2005, Ye et al 2003). 
 
Himmelbach et al. (Himmelsbach et al 2009) demonstrated that Sorafenib, an 
FDA and EU approved drug for the treatment of HCC also inhibits HCV replication in 
cell culture. Sorafenib has been shown as a potent inhibitor of c-Raf that interacts with 
the HCV NS5A. The CTAC inhibitors (e.g. NIM811, Debio 025) for the HCV protein-
interacting partners such as cyclophilins A and B are also in clinical trials. However, due 
to adaptive mutations in the HCV proteins, the drug-resistance is inevitable as reported in 
a number of studies (Yang et al 2008). Our studies suggest that HCV induced stem cell-
like features may contribute to the long-term persistence of HCV and HCV-induced 
aggressive HCC. Therefore, new CTAC inhibitors whose potencies are not compromised 
by the HCV adaptation and drug cocktail with diverse mechanisms of action are needed 
to combat HCV infection.  Such multi-dimensional approach as proposed here is likely to 





Figure 3.1. Possible interactions among HCV, miR-122 and cholesterol biosynthesis 
pathway. The statins block the rate-limiting enzyme, HMGCR. The interaction of viral 
protein NS5A with geranylgeranylated cellular protein FBL2 and HCV RNA are shown. 
NS5A also interacts with lipid droplets and membranes (not shown) CoA, coenzyme A; 










2.   Materials and Methods 
 
Cell Culture, real-time RT-PCR analyses, immunohistochemistry, 
immunofluorescence and confocal microscopy were done as described in Materials and 
Methods, Chapter 2.  
 
2.1.   Culture of normal human hepatocytes (NHH) 
 
Normal human hepatocytes from a donor (16 yr, female, non-smoker, died due to 
head trauma) were purchased from BD Biosciences in crypreserved form (Catalog # 
454550). The cells were stored in liquid nitrogen until needed.  For confocal and 
immunoflorescence microscopy, the cells were cultured/maintained in Hepato-STIM 
Hepatocyte Defined Medium (BD Biosciences) supplemented with Epidermal Growth 
Factor (10 ng/ml)  and 1X antibiotic-antimycotic (Invitrogen) on collagen BD cover slips 
(22 mm).  The cells were incubated at 37°C and 5% CO2, washed after 72 hrs with PBS, 
fixed with formaldehyde and stained with antibodies as described in earlier chapter.  
Alternatively, the NHH were also maintained in BD Matrigel 6-well plate in the Hepato-
STIM complete media to determine their three-dimensional growth pattern.  These NHH 
were subjected to H&E staining, immunohistochemistry, and staining for DCAMKL-1 







2.2. Cell proliferation assay:  
 
 MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was 
purchased from Biotum, Inc. and used according to manufacturer recommendations. To 
investigate cellular toxicity of fluvastatin, 2×104 cells were plated into 96-well plates in 
100 ul regular complete DMEM media. After 24 h, varying concentrations of fluvastatin 
were added and the plate kept at 37 C in 5% CO2 for 72 or 94 h.  The cells were washed 
and fresh media (100 µl) and MTT solution (5 mg/ml in PBS) were added to all wells, 
wrapped the plate in aluminum foil and incubated for 3-4 h at 37 C.  Two hundred µl of 
DMSO was added to each well in order to dissolve the formazan crystals formed as a 
result of the MTT reaction. Absorbance with an enzyme-linked immunosorbent assay 
(ELISA) plate reader at a test wavelength of 570 nm and a reference wavelength of 630 
nm. 
 
3.   Results 
 
3.1.  Fluvastatin reduces abundance of the HCV RNA and NS5B polymerase 
in GS5   cells 
 
Recent studies have shown that statins lower HCV titer in patients (Bader et al 
2008). The HCV-specific drugs and/or IFN with certain statins have also been 
demonstrated to improve efficacy of the treatment (Delang et al 2009, Harrison et al 
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2010).  However, mechanism of action of different statins against HCV is not fully 
understood.  
The HCV subgenomic replicon-expressing GS5 cells were treated with increasing 
amounts of FLV. Since DMSO is a solvent for FLV, similar amounts of the 
solvent/vehicle alone were used in the control culture. The cultures without any drug or 
solvent were considered as positive controls. As shown in Fig. 3.2A, increase in FLV 
concentration from 0 to 5.0 uM caused marked decrease in the HCV RNA (black bar).  
Further increase of FLV (10 uM) did not show additional reduction of the HCV RNA.  In 
contrast, DMSO alone did not reduce the HCV RNA level at any of these concentrations 
(gray bars). The inhibitory effect of FLV on HCV was also confirmed by Western blot 
analysis. The total lysates prepared from untreated and FLV-treated cells revealed that 
the expression of NS5B polymerase is significantly reduced at 5 and 10 uM (Fig. 3.2B, 
upper panel, lanes 5, 6) as compared to the control (lane 1). This reduction was not 
noticed the DMSO treated lysates (lower panel).  These results clearly indicate that FLV 
considerably inhibits HCV RNA and protein levels.   
 
3.2. Effect of mevalonic acid on FLV-led inhibition of the HCV replicon 
  
Mevalonic acid (Mev) is a product of the enzyme HMG-CoA reductase (HMGR) 
and is essential substrate for downstream reactions in the cholesterol biosynthesis 
pathway. Therefore, inhibition of HMGR by FLV can be antagonized and cholesterol 
biosynthesis pathway can be restored by addition of mevalonic acid in the culture media.  
Varying amounts of Mev (5, 10, 15 uM) were added to GS5 culture in the presence of 
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FLV (5uM). The control cultures lacked FLV but were supplemented with DMSO and 
Mev. The HCV RNA levels in these cells were compared with the untreated culture.  
Although, 5 and 10 uM of Mev could not recover the FLV inhibition. However, a modest 
expression level of the HCV RNA was restored at 15 uM of Mev (Fig. 3.3A). The 
DMSO-treated cells alone or with exogenously added Mev did not affect the HCV RNA 
abundance. Next,  5 uM of each FLV, pravastatin (Prav) and  rusovasatin (Ruso) were 
added in the absence or presence (15 uM) of Mev.  Only FLV showed reduction (Fig. 
3.3B, lane 2) in the NS5B level as compared to the untreated control (lane 1).  
Interestingly, addition of 3-fold molar excess of Mev led to very little recovery of the 
NS5B level (lane 3).  Addition of Prav and Ruso to the cell culture in the absence or 
presence of Mev failed to exhibit reduction in the HCV NS5B level under similar 
conditions (lanes 4-7). In similar experiments, we further noticed that the FLV-treated 
GS5 cells displayed marked morphological changes with induced cytoplasmic 
protrusions (Fig. 3.3C-b), which were partially recovered by Mev treatment (Fig. 3.3C-
d).  These changes were not observed for DMSO (Fig. 3.3C-c) or pravastatin treatment 
(not shown).  Our MTT cell proliferation assay on these cells including ASPC1 
(pancreatic cancer cell line) and FCA4 (an HCV replicon expressing Huh7 cell lines) 









 Figure 3.2. Reduction of the HCV RNA and NS5B polymerase abundance by fluvastatin 
treatment in GS5 cells. (A) Real-time RT-PCR for detection of the HCV RNA in DMSO 
(control, gray bar) or fluvastatin (FLV) in DMSO (black bar).  The cells were treated 
with different amounts (0-10 uM in media) of FLV.  Same amounts (ul) of the solvent 
(DMSO) were added in the control samples.  Total RNAs were extracted from the cells 
using Qiagen Rneasy Kit for the PCR.  (B) Western blot for NS5B in FLV-DMSO 
(increasing concentrations from lane 2 through 6) and DMSO alone (Cont.) as indicated. 






3.3. Fluvastatin induces ‘microtubule bundling’ in cancer-related cells but 
not in normal human hepatocytes 
 
The morphological changes in GS5 cells due to FLV-treatment (Fig. 3.3C) 
prompted us to investigate the status of microtubule filaments (MTFs) using confocal 
microscopy. Interestingly, the FLV-treated but not the DMSO-treated GS5 cells exhibited 
extensive ‘bundling’ of the microtubule filaments (Fig. 3.4A).  The induced skeletal 
change was accompanied by the decrease in NS5A-GFP intensities and displacement of 
replication complex from the MTF bundles (Fig. 3.4B, lower panel).  The MTF bundling 
effect was observed in Huh7.5 but was less pronounced (Fig. 3.4C, lower panel).  In 
contrast, normal human hepatocytes were completely resistant to the FLV-induced MTF 
disruption (upper panel). 
 
3.4.  Effect of Fluvastatin on DCAMKL1  
 
Because DCAMKL-1 catalyzes polymerization of tubulins into microtubules, we 
looked into its cellular localization in the FLV-treated and untreated cells. As shown in 
Fig. 3.5, DCAMKL1 localization in GS5 cells was disturbed and dislodged from 
microtubules as a result of the bundling effect induced by FLV (lower panel). This 
bundling and redistribution of  DCAMKL1 did not occur in  DMSO treated cells (upper 
panel).   
The miR-122 has been shown to facilitate the replication of HCV by binding to 
the domain I in the HCV 5’UTR at two adjacent sites (Jangra et al 2010, Jopling 2008, 









Figure 3.3.  Effect of different statins and mevalonate  on the HCV replication, cellular 
morphology and cell survival within three days of the drug treatment. (A) Relative 
abundance of the HCV RNA in FLV-treated cells that were supplemented with 5, 10 and 
15  uM of mevalonic acid (antagonist of FLV).  The untreated culture was used as 
positive control. (B) Western blot for detection of NS5B expression levels in GS5 cells 
treated with fluvastatin (FLV, lanes 2, 3), pravastatin (Prav, lanes 4, 5) and rusovastatin 
(Ruso, lanes 6,7). Lane 1, untreated control. DMSO, vehicle control. (C) Brightfield 
photograph of GS5 cells treated and untreated with various drugs as indicated, 
highlighting morphological sensitivity of the cells by the FLV treatment (b) and its partial 
reversal by mevalonate (d).  a, b; controls. (D) MTT assay for cell proliferation at 72 hrs 
of the FLV and vehicle treatments. ASPC1, pancreatic cell line; FCA4,  hepatoma cell 
line derived from Huh7 and expresses a subgenomic replicon without GFP, otherwise 








Figure 3.4. Effect of FLV on microtubule filaments (MTFs) in GS5 (A), normal human 
hepatocytes [(C), upper panel] and Huh7.5 cells [(C), lower panels] shown by confocal 
microscopy.  (B) Higher magnification for vehicle (DMSO alone) treated GS5 cells [(A), 
upper panel] showing localization of the HCV replication complexes (green), MTFs (red) 








The miR-122 has also been implicated in cholesterol biosynthesis.  For these 
reasons, we checked if primary miR-122 RNA is affected by the FLV in GS5 cells. As 
shown in figure 3.6A, DCAMKL-1 RNA (black bar) but not the pri-miR-122 (Fig. 3.6B) 
level was reduced to significant extent by the FLV treatment.  In the control DMSO 
sample neither DCAMKL-1 nor pri-miR-122 RNA levels were affected.  These results 
clearly suggest that FLV regulates expression of DCAMKL-1 at its RNA level, and the 
existing DCAMKL-1 localization to the MTFs is severely affected.   The net result of 
FLV effect is reflected by  inhibition of the HCV expression in these cells.   
 
3.5. Cirrhotic liver nodules of chronic HCV patients show overexpression of 
DCAMKL1 and CK19  
 
As a continuing effort to unravel the mechanism of HCC development, we 
examined liver biopsy samples from chronic HCV patients and liver tissue arrays 
representing various stages of liver diseases.  An example of immunohistochemical 
staining result is shown in Fig. 3.7. Strikingly, in agreement with the results obtained for 
our cell culture and xenograft experiments, the biopsies exhibited overexpression of 
DCAMKL1 and CK19 in the cirrhotic liver nodules which are considered to be risk 
factor for hepatocarcinogenesis  (Fig. 3.7 lower panel). DCAMKL-1 expression was also 
shown to be increased in cirrhotic liver tissue as shown by our tissue microarray studies 
















Figure 3.5. Immunoflorescence microscopy localization of DCAMKL-1 (red) in relation 
to MTFs (magenta) and replication complexes (green).  The GS5 cells were treated with 









The findings described in this chapter are coherent with those in Chapter 2.  Our 
data further support possible use of the FDA-approved drug, fluvastatin as an adjuvant to 
the available HCV therapeutics in order to reduce the risk of HCC development.  In 
addition, it is likely that FLV along with DCAMKL-1 antagonist  would effectively block 
both chronic HCV infection as well as HCV-induced HCC. 
 
4.   Discussion 
 
We demonstrated inhibitory effects of fluvastatin (FLV) on the abundance of 
HCV RNA and NS5B polymerase in cell culture.  This pleiotropic effect was only 
partially restored by large excess (3 times molar excess) of the FLV antagonist 
(mevalonate), which indicates involvement of additional mechanism for the FLV-led 
inhibition of HCV besides partial contribution of the cholesterol biosynthesis pathway.   
This notion is also supported by the fact that only fluvastatin but not pravastatin reduces 
the HCV NS5B level and exerts induced-bundling of microtubule filaments. One of the 
obvious consequences of the MTF bundling was highly pronounced morphological 
changes in GS5 cells than that of the parental Huh7.5 cells. Our cell viability assays 
suggested that these cells were still alive during 3-day of FLV treatment. Interestingly, 
normal human hepatocytes derived from a healthy donor were completely tolerant to 







Figure 3.6. Effect of fluvastatin on the abundance of DCAMKL-1 and pri-miR-122 
RNAs.  The GS5 cells were treated with varying amounts of FLV (black bar) or DMSO 
alone (gray bar) and total RNAs isolated from these cells were subjected to real-time RT-








cancer cells induced by FLV is likely affecting microtubule dynamics and its associated 
proteins. In previous chapter, it was demonstrated that HCV induces overexpression of 
the microtubule-associated putative stem cell marker, DCAMKL-1.  Houchen and 
colleagues from this department (May et al 2008, Sureban et al 2009) have previously 
shown that both pancreatic and colon cancer cells exhibit high expression of DCAMKL-1 
and develop tumors in a mouse xenograft model. However, when DCAMKL-1 
expression was inhibited in the tumors, the tumor size shrinks dramatically. These 
observations prompted us to investigate the status of DCAMKL-1 in FLV-treated cells.  
We demonstrated that DCAMKL-1 RNA abundance was reduced in these cells and the 
existing DCAMKL-1 protein was aggregated and dislodged from the microtubule 
filaments. As a result, the HCV replicon expression was significantly reduced because 
intact MTFs and DCAMKL-1 (as presented in chapter 2) are required for the HCV 
replication (Lai et al 2008, Roohvand et al 2009) (Wolk et al 2008).  
 
            HCV is regarded as a lipoviroparticles because lipids play pivotal roles in the 
organization of HCV particles as well as infectious processes of the virus. Cholesterol 
esters account for nearly half of the total lipid content of cell culture generated HCV 
infectious particles.  Both HCV NS5A and core proteins are known to associate with lipid 
droplets (LD) that are cellular lipid storage organelles involved in lipid homeostasis. 
Chronic hepatitis C virus (HCV) infection affects host lipid metabolism and induces LD 








Figure 3.7. CK19 and DCAMKL-1 overexpression in an HCV-positive patient liver 
detected by immunohistochemistry.  Sample 2 represents neoproliferative cells in the 
cirrhotic liver biopsy taken after 2 years of the first biopsy (Sample 1) from the same 










complexes consists of the viral NS proteins including NS5A and lipid rafts that are 
enriched in caveolin-2, sphingomyelin and cholesterol. It has been suggested that 
geranylgeranylation of a cellular protein, F-box/leucine-rich repeat protein 2 (FBL-2) in 
an HMG-CoA reductase (HMGCR)-dependent manner is required for its interaction with 
the HCV NS5A protein and its role in HCV RNA replication. In such situation, 
supplementation of mevalonate would have completely rescued the HCV replication as it 
functions as a substrate downstream of HMGCR activities.  These observations also 
argue FLV-mediated control of HCV abundance in favor of its selective effects on 
MTFs-dependence DCAMKL-1.  Because the HCV replicon expressed in GS5 cells lacks 
all of the structural proteins (C, E1 and E2) and assembly of the particle, the observed 
FLV effect is likely to be directed at the translation and replication steps.  
 
Chronic HCV infection over several months to a few years results in cirrhosis 
including disruption of normal liver architecture and development of regenerative 
nodules.  We examined multiple nodules from HCV-positive cirrhotic liver.  The 
immunohistochemistry results clearly showed overexpression of both DCAMKL-1 as 
well as CK19 in these nodules.  In many cases, such nodules are considered to be 
precursors for the development of HCC (Caillot et al 2009). Therefore, FLV inclusion in 
the treatment of chronic HCV infection will have multiple advantages.  First, it will 
reduce cholesterol biosynthesis and disrupt the excessive accumulation of lipid droplets 
and lipid-rafts, which are required in the replication, assembly and intracellular transport 
of HCV.  Second, generally well-tolerated fluvastatin may reduce the risk of HCC 
development due to its effects on DCAMKL-1 and MTFs.  It has been shown by other 
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investigators that the plieotropic effects of statins act as adjuvant to other HCV targeting 
drugs, and may sensitize the cells against anti-neoplastic drugs (Demierre et al 2005).   
 
In conclusion, the studies presented in this chapter clearly strengthen this notion 
and recommends inclusion of fluvastatin with new HCV-specific drugs (e.g. boceprevir) 









Chapter Four: Mechanism of c-Src proto-oncogene expression in  
HCV expressing cells 
 
1.    Introduction 
 The studies on tumor xenotransplantation (Chapter 2, Fig. 2.3E) suggest that c-
Src, a prominent member of the non-receptor tyrosine kinase family, was highly 
expressed and activated in the area rich in DCAMKL-1.  This led us to believe that c-Src 
expression may be important factor for the HCV-induced carcinogenesis. The level of 
cellular Src (c-Src) protein, is known to increase in a variety of tumors (Fizazi 2007, 
Horn et al 2003).  However, it is not known whether the enhanced expression is regulated 
by transcriptional and/or post-transcriptional mechanisms.  The c-Src protein promotes 
cell differentiation, tumor growth, metastasis and angiogenesis (Bjorge et al 2000, Finn 
2008).   It activates STAT3 which transcriptionally regulates expression of Bcl-XL, c-
Myc and cyclin D1 leading to activation of anti-apoptotic and cell-cycle progression 
pathways (Diaz et al 2006, Garcia et al 2001).   It has been shown that activated c-Src-
focal adhesion kinase (FAK) complex promotes cell mobility, cell-cycle progression and 
cell survival.  The c-Src activities are also important for promoting VEGF-associated 





Post-translational modifications such as phosphorylation and myristoylation are 
key regulators of the c-Src activities.  While non-myristoylated c-Src readily moves to the 
nucleus in G0 and at the G1/S phase, myristoylation at the N-terminus is required for its 
membrane attachment and transforming activities (David-Pfeuty et al 1993, Oneyama et 
al 2008).        
 
The intramolecular interaction between its SH2 domain and phosphorylated 
Tyr530 (numbered according to NM_198291) residue at the C-terminus induces closed or 
inactive conformation in the c-Src molecule.  Under basal conditions in vivo, 90-95% of 
Src is found in this state (Zheng et al 2000).  The dephosphorylation of Tyr530 by protein 
tyrosine phosphatase (PTP) and autophosphorylation of Tyr419 by its kinase domain 
causes induction of an enzymatically active, open conformation(Bjorge et al 2000, Fizazi 
2007).  
 
The Src gene is composed of 14 exons (Bonham and Fujita 1993, Bonham et al 
2000).  Transcription of this gene in hepatoma cells from two different promoters and 
alternative splicing results in mature transcripts that differ only in the extreme 5’ ends but 
encode the same 60 kDa c-Src protein (Fig. 4.1A).  The c-Src Type-1A mRNA contains a 
350 nt long 5’ noncoding or untranslated region (5’NCR or 5’UTR) with multiple AUGs 
located at nt positions 147, 179, and 351 (Fig 4.1B).  However, only AUG351 is used to 
initiate translation of the c-Src open reading frame (ORF).  The Type-1a c-Src transcript 
contains a 451 nt long 5’NCR and differ with Type-1A only in the first exon (1A or 1a) 




transcripts.  Hepatoma cells have been shown to express both transcripts (Bonham et al 
2000). The regulatory role(s) of these noncoding/untranslated elements during translation 
of c-Src mRNAs and their role(s) in c-Src overexpression are not known.  
 
Most eukaryotic mRNAs are translated by cap-dependent mechanism where 
eIF4F complex binds to the 5’ cap structure through its eIF4E subunit (Sonenberg and 
Hinnebusch 2007).  This binding event results in activation of mRNA and assembly of 
48S pre-initiation complex.  The 48S complex scans mRNA in 5’ to 3’ direction until an 
appropriate AUG initiation codon is encountered, which is followed by joining of the 60S 
subunit (Sonenberg and Hinnebusch 2007).  Many cellular conditions such as apoptosis, 
stress, mitosis, heat-shock, hypoxia, infections and nutrient deficiency alter the function 
of normal translation initiation machinery. This is largely affected by post-translational 
modifications (e.g. phosphorylation) and/or cleavage of canonical initiation factors (e.g. 
eIF4B, eIF3, eIF2a and eIF4G family members) (Baird et al 2006, Sonenberg and 
Hinnebusch 2007, Wek et al 2006).  A considerable number of cellular and viral mRNAs 
have been shown to be translated by cap-independent mechanism due to the presence of 
an IRES element in the mRNAs (Hellen and Sarnow 2001, Johannes and Berger 1993).  
Nearly 125 IRES elements have been described in a variety of species ranging from 
viruses to humans (Baird et al, 2006).  The IRES elements have been detected in a 
number of eukaryotic mRNAs that encode proteins involved in signal transduction 
pathways, gene expression and development, differentiation, apoptosis, cell-cycle or 




Hinnebusch 2007). For example, cellular stress causes dephosphorylation of eIF4E and 
hypophosphorylation of 4E-BPs, both of which are unfavorable for the assembly of 
translation pre-initiation complex by the cap-dependent mechanism (Gingras et al 1999, 
Sonenberg and Hinnebusch 2007).  However, under these conditions, Bcl-2, XIAP, 
eIF4G, VEGF, ODC, PDGF, PITSLRE, c-Myc family members, and a whole host of 
proteins maintain their presence due to their IRES-controlled translation(Chappell et al 
2000, Johannes and Sarnow 1998, Nanbru et al 1997, Semler and Waterman 2008, 
Spriggs et al 2008).   
 
All of the viral and cellular IRESs initiate translation of a downstream open 
reading frame (ORF) by cap-independent mechanism in spite of their rich structural 
diversities (Filbin and Kieft 2009). The distinct structural features allow the IRESs to 
attract different set of canonical and non-canonical translation factors for their efficient 
activities and/or regulation.  For examples, some of the viral and cellular IRESs require 
initiation factors such as eIF4G and PABP while others show enhanced activities when 
these factors are cleaved or their function is inactivated (Holcik and Sonenberg 2005). A 
few of the IRESs seek support from ITAFs (IRES-specific trans-acting factors) such as 
hnRNP family members, PTB, La antigen and PCPB for their efficient function (Ali and 
Siddiqui 1997, Semler and Waterman 2008, Spriggs et al 2008, Wang et al 1995).  The 
IRESs also exhibit variations in the mode of assembly of pre-initiation complex.  
Poliovirus-like IRESs recruit the 48S pre-initiation complex upstream of the initiation 




extensively studied encaphalomyocarditis virus (EMCV) IRES recruits the pre-initiation 
complex at the initiation site that includes AUG (Baird et al 2006, Filbin and Kieft 2009).  
The IRESs of hepatitis C virus (HCV, a hepacivirus), classical swine fever virus (CSFV, 
a pestivirus), cricket paralysis virus (CrPV, a dicistrovirus) and simian picornavirus type 
9 (SPV9) constitute a distinct class because of their ability to directly bind and make 
multiple contacts with the 40S ribosomal subunit (Filbin and Kieft 2009, Jan and Sarnow 
2002, Lancaster et al 2006, Pestova et al 1998).  The assembly of productive initiation 
complexes on these IRESs is energy-efficient and can ignore the need of several critical 
translation initiation factors (eIFs 4F/4A/4B/1/1A) that are controlled by a variety of 
external and internal cellular regulators (Robert et al 2006, Spriggs et al 2008).  This 
‘40S-binding signature’ has not been reported for the known cellular IRESs. 
 
2.   Material and Methods 
 
 2.1. Plasmid Constructs  
  
 RNA was isolated from hepatoma-derived Huh7 cell line using Qiagen RNeasy 
kit.  Nucleotides 1-383 of the Type-1A c-Src mRNA were amplified from the total RNA 
using high fidelity RT-PCR Kit (Promega) and a pair of primers (Sense: 
5’CATAGCAAGCTTGCCGGAGCGGCCAGGCCGCCGTCTGC3’; Antisense: 
5’GCGCCGCTGTCATGAGGCATCCTTGGGCTTGCTCTTGTTGCTACC3’, 
restriction enzymes sites are underlined).  The amplified DNA contains wild type full-




PCR products were digested with HindIII and BspHI for ligation into a vector backbone. 
The backbone was created by digestion of a previously described plasmid pT7C1-DC29-
332 (Wang et al 1993) with HindIII and NcoI and the PCR products were ligated at this 
site after restriction digestion.  The resulting plasmid p5'Src-FLuc contains T7 promoter 
at the 5’ end of the c-Src sequence which is followed by ORF of firefly luciferase (FLuc) 
and ends with oligoA tail.  The in vitro transcription of the HpaI digested  plasmid by T7 
RNA polymerase produces an RNA containing the entire 5’NCR followed by coding 
sequences representing N-terminus 11 aa (MGSNKSKPKDA) of c-Src fused with the 
FLuc ORF ending with poly(A) tail. The plasmid p5'Src∆C-FLuc was similarly 
constructed as described for p5'Src-FLuc except that it lacks 33 nt of the c-Src coding 
sequence.  To construct this plasmid, the c-Src PCR-amplified DNA described above was 
digested with HindIII and NcoI and cloned at the same site in the vector backbone.  In 
both cases the Kozak sequence context was maintained at the translation site.  The 
sequence of each construct was verified by restriction enzyme digestion and Big Dye 
DNA sequencing method (Applied Biosystems).    
 
The mutant plasmids p5'Src∆1-FLuc, p5'Src∆2-FLuc, p5'Src∆3-FLuc are derived 
from the p5'Src-FLuc except that these plasmids have deletions of 19 (nt 216-350), 253 
(nt 95-348) and 171 (nt 47-216) bases in the c-Src motif respectively.  The plasmids were 
constructed by appropriate restriction digestion and religation of the open ends. A dual 




luciferase (RLuc) gene and stop codon upstream of the c-Src 5’NCR in the original 
plasmid p5'Src-FLuc.   
 
The plasmid 5’PV-FLuc contains wild type, full-length poliovirus (PV, Mahoney 
strain) 5’NCR (nt 1-742) cloned in frame with FLuc ORF followed by poly(A) tail.  The 
mutant plasmid 5’PV(D286-605)-FLuc was constructed by restriction enzyme digestion 
of the 5’PV-FLuc plasmid with BlpI and BsaBI followed by filling with T4 DNA 
polymerase and religation with Quick T4 DNA ligase (New England BioLabs).  The 
resulting plasmid contains a deletion of 319 bp (nt 286-605) in the PV 5’NCR.     
 
2.2.  In vitro transcription   
 
The plasmids p5'Src-FLuc, p5'Src∆1-FLuc, p5'Src∆2-FLuc, p5'Src∆3-FLuc and 
p5'Src∆C-FLuc were linearized with HpaI and transcribed with T7 RNA polymerase to 
produce luciferase reporter RNAs.  The uncapped RNAs were prepared with Promega’s 
RiboMax Large Scale RNA production kit.  The capped RNAs were synthesized in the 
presence of the ARCA cap analogue using mMassage mMachine Ultra kit (Ambion) in 
accordance with the manufacturer's instructions.  The transcribed RNAs were passed 
through G25 column and purified by extraction with phenol:chloroform:isoamyl alcohol 
(PCI) followed by water-saturated cold ether.  Following precipitation and washing with 
70% ethanol, the final preparations were dissolved in RNase-free water and checked for 
integrity of RNAs by formaldehyde-agarose gel electrophoresis. Concentrations of RNA 




FLuc was linearized with XbaI and transcribed with T7 RNA polymerase in the presence 
of [a-32P]CTP.  The 5’PV(D286-605)-FLuc was similarly digested with XbaI and 
transcribed for preparation of an inactive IRES control probe.   The probes were purified 
using Qiagen RNeasy purification method.  The plasmid pRL-HCV1b encodes upstream 
Renilla luciferase followed by the HCV IRES (nt 1-357 of the HCV genotype 1b) linked 
to the second reporter FLuc (Collier et al 1998).  The plasmid was linearized with HindIII 
and transcribed in the presence of cap analogue using T7 RNA polymerase.   
 
2.3. Cell culture and preparation of cell lysates 
   
Huh7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 1x Pen/Strep and 10% fetal bovine serum (Invitrogen), and 
maintained at 37°C and 5% CO2.  HeLa S3 cultures were carried out in spinner flask 
containing Joklik modified minimum essential medium Eagle (Sigma) supplemented with 
5% bovine calf serum, 2% fetal clone II (Hyclone), 1x Penicillin/Streptomycin, and 
incubated at 37°C and 5% CO2.  
 
HeLa translation lysates (S10) and lysates containing initiation factors (IFs) were 
prepared according to the protocol described by Barton and colleagues (Barton et al 
1996).  The rabbit reticulocyte lysate nuclease-treated (RRL) was purchased from 
Promega.  The total lysates from cultured Huh7 cells were prepared using M-PER Kit 







2.4. In vitro translation of RNAs   
 
The in vitro transcribed wild type 5’Src-FLuc and its mutant derivatives were 
translated in HeLa cell-free system.  The standard HeLa cell-free translation mixtures 
contain 20 ul S10, 10 ul IFs, 5 ul 10X buffer (155 mM HEPES-KOH, pH 7.4, 600 mM 
potassium acetate, 10 mM ATP and 2.5 mM GTP, 300 mM phosphocreatine, 4 mg/ml 
creatine phosphokinase), 20 units RNasin, 5 to 10 ug RNA template in a 40 ul final 
volume.  One microliter [35S]Methionine  was added for radio-labeling of the newly 
synthesized proteins.  The translation mixtures were incubated for 1 to 2 hr at 30°C, and 
the FLuc activity was assayed using 2 ul aliquots. For detection of protein bands, the 
samples were subjected to SDS-PAGE followed by autoradiography.  For detection of the 
5’Src-RFLuc RNA expression, a dual luciferase assay protocol (Promega) was employed, 
and renilla and firefly luciferase activities were simultaneously assayed.  Varying 
amounts of m7GDP or m7GTP were added in the standard HeLa translation mixtures for 
inhibition of cap-dependent translation.  Unmethylated GDP or GTP served as negative 
control.  Translation of the RNA in RRL was carried out as described in the supplier’s 
protocol (Promega).  
  
2.5.  RNA stability assay  
  
Equal amounts of 32P-labeled wild type or mutant reporter RNAs were incubated 




using RNeasy Kit (Qiagen).  The recovered RNAs were subjected to formaldehyde-
agarose gel electrophoresis followed by autoradiography of the dried gel.  The bands of 
18S or 28S rRNA in each lane were measured by ethidium bromide staining before 
drying the gels.  During transfection experiments, 32P-labeled reporter RNAs (1-2x106 
dpm) were transfected into Huh7 cells using standard transfection method and total 
RNAs were isolated.  The radioactive full-length RNAs were detected by 
autoradiography. 
 
2.6.  Transfection of RNA into cells   
  
Huh7 cells were transfected with in vitro transcribed RNAs using Lipofectamine 
2000 reagent (Invitrogen) according to the manufacturer’s protocol.  After 3, 5, 8, 24 and 
48 hours post-transfection, the cells were harvested and resuspended with lysis buffer 
(100 mM potassium phosphate pH 6.8, 1 mM DTT, 0.5% Igepal).  The samples were 
then subjected to two freeze-thaw cycles and supernatants were assayed for Luc 
activities.   For fluorescence microscopy, the cells were grown on coverslips (Fisher 
Scientific) followed by RNA transfection.  The cells were fixed with 4% formaldehyde 
48 hours post-transfection, permeabilized and stained with anti-firefly luciferase 
monoclonal antibody (Bionovus).  A FITC-labeled secondary conjugate was used to 






2.7.  Isolation of 40S ribosomal subunit  
 
HeLa S10 lysate was prepared from HeLa S3 cells grown in a spinner flask as 
described by Barton and colleagues (Barton et al 1996).   The  ribosomes were pelleted 
from S10 lysate by centrifugation in Ti70.1 rotor (Beckman, 45,000 rpm) for 3h at 4 °C 
and the pellet was resuspended in buffer A (20 mM Tris-HCl, pH 7.5, 2 mM DTT, 50 
mM KCl, and 4 mM MgCl2 ) at a concentration of 150 U/ml measured at A260 as 
described by Pisarev et al. (Pisarev et al 2007).  Puromycin  (1 mM) and KCl (0.5 M) 
were added, stirred at ice-bath for 10 min followed by incubation for 10 min at 37°C.  
The mixture was then loaded onto a 10%-30% sucrose density gradient and centrifuged 
for 16 h at 4 °C in a Beckman’s SW28 rotor (22,000 rpm).  The peak fractions containing 
40S ribosomes (as determined by the presence of only 18S rRNA) were pooled and 
concentrated in Ultracell-100 K (Millipore).  The final preparation was dialyzed in buffer 
C (20 mM Tris-HCl pH 7.5, 2 mM DTT, 100 mM KCl, 2 mM MgCl2, 0.25 M sucrose),  
aliquoted and stored at -80 °C (Pisareva et al 2008). 
 
2.8. Sucrose density gradient analysis   
 
Capped or uncapped 32P-labeled mRNAs were incubated in standard HeLa 
translation lysates that were treated with 1mM GMP-PNP for 5 min on ice-bath.  The 
mixtures were then incubated for 15 min at 30°C, layered onto a 10%-30% sucrose 




magnesium acetate, and 2 mM DTT), and centrifuged for 3 hours  at 45,000 rpm and 4 
°C in a SW-51 rotor.  Fractions (250 ul) were collected from the bottom of gradient and 
analyzed by scintillation counter.  Total RNAs from peak fractions were isolated using 
Qiagen RNeasy Mini column for analysis of the RNA contents in the fractions. 
 
For 40S-IRES binary interaction assay, the 32P-labeled c-Src IRES or  a 
nonspecific RNA probe derived from 5’PV(D286-605) as scrambled IRES was mixed 
with purified HeLa 40S subunit in buffer K containing 20 U RNasin in a final volume of 
40 ul and incubated for 15 minutes at 30°C.  The reaction mixtures were analyzed by 
sucrose density gradient method as described above.  A sample of RNA probe without 
40S was used to specify position of the free probes during centrifugation. 
     
3.   Results 
 
3.1.  Cellular stress induces c-Src overexpression as well as its activation 
 
Our mouse xenograft experiments (Chapter 2, Fig. 2.3E) clearly demonstrated 
that sporadic  DCAMKL-1 expressing cells were embedded in the GS5 tumor areas 
where c-Src oncoprotein was overexpressed.   It has been established by other studies that 
stress is one of the culprits for inducing tumorogenesis (Alvarez et al 2006, Chang et al 
2007, Diaz et al 2006, Horn et al 2003).Since HCV induces oxidative stress and NF-k  
(Waris et al 2005), we investigated molecular mechanism of c-Src expression under 





Thapsigargin (TG) causes eIF-2 phosphorylation resulting in global translation 
inhibition and ER stress response due to inhibition of Ca2+-ATPase activities (Chao et al 
1997, Wong et al 1993). A modest increase in the total c-Src protein level was observed 
in DMSO-TG-treated cell lysates as compared to the untreated (control) or DMSO alone-
treated lysates (Fig. 4.1.A).  The c-Src mRNA level remained unchanged in these cells 
(Fig. 4.1B). Serum-deprivation of cells also causes suppression of cap-dependent 
translation due to competitive inhibition of eIF4E binding to the 5’ cap structure by 
poly(A)-specific ribonuclease (PARN) (Seal et al 2005), and phosphorylation of eIF2a 
(Wek et al 2006).   When Huh7 cells were subjected to serum starvation, the total c-Src 
protein level was moderately enhanced within 72 hours (Fig. 4.1.C, minus) as compared 
to the control (plus) although the c-Src mRNA level was not affected (Fig. 4.1.D).  
 
3.2. Characteristics of the computer-generated c-Src RNA structures  
 
The 5’NCRs in the c-Src transcripts have been shown to be relatively longer than those in 
most cellular mRNAs (Bonham and Fujita 1993).  Sequence analysis revealed multiple 
pyrimidine-rich motifs and two cryptic AUGs with short ORFs at positions 147 and 179 
in the 350-nt long Type-1A 5’NCR (Fig. 4.2).  Only the AUG located at position 351 is 
known to serve as the initiator codon in this mRNA.  Our nucleotide blast search using 
BLASTN 2.2.20+ program (Schwartz et al 2000)revealed that the exon 1C and 11 amino 
acid N-terminus coding sequences are highly conserved in humans, chimpanzees and 
rhesus monkeys (94%-100% identity) whereas mouse sequences in this region are 76-




NM_198291). Using M-Fold program  (Zuker 2003), we examined a number of predicted 
secondary structures representing three segments (nt 1-353, 1-383, 1-410) of the Type-1A 
c-Src mRNA.  A representative structure (dG = -135) for nt 1-383, which was found to be 
similar to the structure obtained for nt 1-410 segment, is shown in (Fig. 4.3)  This Y-
shaped secondary structure appears to contain three domains designated as domain I, II 
and III.  We further observed that a large portion of the domains I and II were conserved 
in the structures predicted for all three c-Src segments.  In addition, a high degree of 
conservation in the apical loops contributed by AACAAGA (nt 360-366), GUGCCA (SL 
II, nt 289-294) and UAUUUC (SL III, nt 255-260) motifs was also noticed in the 
predicted structures.  The structures in domain  III, however, showed less conservation 
among various structures generated for the three c-Src segments.  A 14 nt pyrimidine 
(Py)-rich motif (nt 330-344) is located 6 nt upstream of the initiator AUG, which 
conforms Py-tracts found in many viral IRESs.  These characteristics and the Y-shaped 
architectural features are considered as important elements of many viral and cellular 
IRESs (Le and Maizel 1997). The predicted structure for the c-Src nt 1-353 that 
represents the entire 5’NCR and AUG codon lacked a significant portion of domain II 
structure. 
 
3.3.  A c-Src mRNA motif supports cap-independent translation of reporter 
RNAs   
 
Firefly luciferase (FLuc)-based reporter mRNAs were engineered to test if the c-





      
 
Figure 4.1. A, The cytoplasmic lysates from experiments described in section B (above) 
were subjected to Western blot for the total c-Src protein with monoclonal anti-Src 
antibody (clone 327, Santa Cruz, upper panel) or anti-actin antibodies (lower panel).  B, 
Northern blot analysis of total RNA extracted from Huh 7 cells described in section B, 
probed with 32P-labeled oligonucleotide corresponding to nt 320-350 of the c-Src 5’NCR 
(upper panel).  Lower panel shows 18S rRNA in the same samples.  C,  Total c-Src level 
in Huh7 cell lysates cultured for 72 hrs in serum-deprived (indicated as minus) or 10% 
serum containing (plus) media.  Western blot was carried out with anti-Src antibody as 
described above.  D,  Northern blot for probing c-Src mRNA (as described above) in total 
RNA extracted from Huh 7 cells cultured in serum-starved (minus) and serum 
supplemented (plus) regular media.  The 18 S rRNAs in each lane is shown in the lower 
panel. 













Figure 4.2. A, Organization of the c-Src gene.  Transcription from two promoters 
(indicated as P) and alternative splicing result in Type-1a (NM_005417) and Type-1A 
(NM_198291) mRNAs in liver cells.  Both transcripts differ only in the 5’ distal region of 
the 5’NCR.  The sequence of the exons 1B and 1C and open reading frame (ORF) are 
shared in both transcripts (35).  AUGi, initiator AUG codon.  B, Schematic of the Type-
1A 5’NCR.  Two cryptic AUGs at nt 147 and 179, the initiator AUG at nt 351, and a 
pyrimidine-tract (nt 330-344) located 6 nt upstream of the initiator AUG are shown.  The 
gray lines with arrows on both sides show sequence locations in different putative 
domains whereas similar arrows with black solid lines indicate position of the conserved 






motif downstream of the initiator AUG in the c-Src mRNA forms conserved stem-loop 
structure at the translation initiation site (Fig. 4.3), we included the region with the 
5’NCR for engineering a parent reporter 5’Src-FLuc RNA.  The RNA contains c-Src nt 
1-383 (full-length 5’NCR plus 33 nt of the coding region) that is fused in-frame with 
luciferase ORF and ends with poly(A) tail (Fig. 4.4A).  In vitro transcribed capped and 
uncapped RNAs were translated in rabbit reticulocyte cell-free lysate (Michel et al 2000, 
Soto Rifo et al 2007) in the presence of [35S]Methionine and the synthesized products 
were visualized by autoradiography.  As expected, the capped 5’Src-FLuc RNA was 
translated to produce active luciferase protein (Fig. 4.4B, lane 3). than its capped 
counterpart (lane 3). During the assay, we used a reporter RNA [5’PV(D286- 
Interestingly, the uncapped 5’Src-FLuc RNA was also translated but with higher 
efficiency (lane 2) (from nt 286 through 605).  Thus, the noncoding region (420 nt) in the 
mutant PV construct represents nt 1-285 followed by nt 606-746 of the PV 5’NCR.  This 
PV region, although, is known to form stable stem-loop structures, provides stability to 
the RNA and binds a number of cellular factors (Murray et al 2001), failed to support 
translation of FLuc in RRL (lane 4).  However, synthesis of FLuc was successfully 
achieved when the same RNA had 5’m7G cap structure (lane 5). These results clearly 
demonstrate that the c-Src nt 1-383 allows cap- independent translation of downstream 
ORF and its activity is enhanced when cap function is absent. The translatability of the 
mRNA constructs was further tested in HeLa cell-free translation lysates which has been 
widely used for investigating IRES-mediated translation initiation (Barton et al 1996).  






Figure 4.3.  Computer-assisted folding of the Type-1A c-Src mRNA sequence.  The 
Zucker’s M-Fold program (version 3.2, 41) was used for prediction of the secondary 
structures representing various segments of the c-Src mRNA.   Only a representative 
structure of the c-Src nt 1-383 that includes the entire 5’NCR followed by 33 nt coding 
sequence, is shown here.  The initiator AUG at position 351 (arrow), and putative stem-





FLuc, Fig. 4.4C, lane 4) and 5’Src-FLuc (lane 2) were efficiently translated while the 
mutant 5’PV(D286-605)-FLuc again failed to support synthesis of luciferase (lane 3).  
Next, we examined the c-Src 5’NCR- promoted translation in the context of a dicistronic 
mRNA (5’Src-RFLuc). The RNA is similar to the monocistronic 5’Src-FLuc RNA except 
that it contains renilla luciferase (RLuc) ORF and stop codon upstream of the c-Src 
sequence (Fig. 4.5A).  The in vitro transcribed capped RNA was transfected into 
hepatoma Huh7 cells for 3 hr and the lysates were subjected to dual luciferase assay.  As 
shown in Fig. 4.5B, both ORFs were translated in these cells.  The capped dicistronic RL-
HCV1b and RL-Vector RNAs were used as positive and negative controls respectively 
during the transfection.  The RL-HCV-1b is similar to the 5’Src-RFLuc (Fig. 4.5A) 
except that the translation of downstream FLuc ORF is controlled by the HCV IRES 
instead of the c-Src IRES.  In RL-Vector, the c-Src IRES between upstream RLuc and 
downstream FLuc ORF is deleted.  Both of the RNAs produced results as expected 
(Appendix 5).  In a parallel experiment, total RNAs isolated from the dicistronic 5’Src-
RFLuc RNA-transfected cells were subjected to Northern blot analysis using a 32P-
labeled oligonucleotide probe that detects 3’ end of FLuc ORF.  The result showed that 
the dicistronic RNA was intact in the transfected cells (Fig. 4.5C, lane 3). The migration 
of isolated RNA was similar to that of in vitro transcribed dicistronic RNA (lane 2), and 
was not cleaved into monocistronic form (lane 1). The 5’Src-FLuc RNA encodes a 
chimeric firefly luciferase with aa 1 to 11 (MGSNKSKPKDA) of the c-Src protein at its 








Figure 4.4. c-Src 5’NCR-mediated translation in cell-free lysates.  A, Organization of in 
vitro transcribed uncapped reporter RNAs.  The 33 nt coding sequence (dotted box, C), 
and Kozak sequence are shown at translation initiation site. The solid line represents 
5’NCR.  An, poly(A) tail.  B,  Five ug of uncapped (lanes 2, 4) and capped (lanes 3, 5) of 
5’Src-FLuc (lanes 2, 3) or 5’PV(D286-605)-FLuc (lanes 4, 5) RNAs were translated in 
RRL for 1.5 hr in the presence of [35S]Methionine.  The FLuc protein bands were 
visualized by autoradiography after SDS-PAGE.  Two  ul of the translation lysates were 
assayed for enzymatic activity (shown as RLU) of FLuc using D-luciferine substrate.  
Lane 1, translation without exogenous RNA (control).  C, Translation of uncapped 5’Src-
FLuc (lane 2), 5’PV(D286-605)-FLuc (lane 3) and 5’PV-FLuc (lane 4) RNAs in HeLa 








membrane localization and translocation of the protein into the nucleus (David-Pfeuty et 
al 1993, Resh 1999).  Transfection of an uncapped 5’Src-FLuc RNA into Huh7 cells 
resulted in the synthesis of luciferase protein that was primarily localized in the nucleus 
and perinuclear membranes (Appendix 4).  This observation was in sharp contrast to the 
diffused cytoplasmic localization of luciferase that was encoded by 5’HCV-FLuc RNA in 
which translation of FLuc occurs under the control of HCV IRES. The resulting FLuc 
lacks c-Src aa 1 to 11 motif. These results suggest that the luciferase synthesized from 
5’Src-FLuc RNA contains the c-Src protein motif, which is possible when translation is 
initiated at the authentic AUG351 (also see Fig. 4.6 for translation of 5’SrcD1-FLuc). 
 
3.4.  Identification of an IRES element in the c-Src mRNA 
   
 We introduced several deletion mutations in c-Src motif of the 5’Src-FLuc RNA 
to determine its putative IRES function.  The mutant 5’SrcDC-FLuc is similar to the wild 
type 5’Src-FLuc RNA except that it lacks the c-Src coding sequence (nt 354-383, Fig. 
4.6A).  The mutant 5’Src-D1-FLuc contains a 19 nt deletion (nt 344-362).  This deletion 
resulted into the loss of Kozak sequence and a major portion of SLI structure at the 
translation initiation site (Figs. 4.3 and 4.6A).  As shown in Fig. 4.6B, both of the 
deletions caused dramatic reduction in the synthesis of FLuc (lanes 4, 7) as compared to 
the wild type RNA (lane 3).  Similarly, the 5’SrcD2-FLuc mutant RNA that contains a 
large deletion (nt 95-348) upstream of initiator AUG also failed to support efficient 
synthesis of FLuc (lane 5).  Unlike these mutants, a 5’SrcD3-FLuc RNA that maintains nt 












Figure 4.5.  c-Src 5’NCR-mediated translation in Huh7 cells.  A,  Schematic of an in 
vitro transcribed dicistronic reporter mRNA (5’Src-RFLuc).   B,  The Huh7 cultured cells 
(80% confluency, 50 mm dish) were transfected with 10 ug capped 5’Src-RFluc for 3 hr, 
and renilla and firefly luciferase activities were assayed in the cytoplasmic fractions.  
Each transfection was carried out in triplicate, and the experiment was repeated three 
times to confirm the results.  The cytoplasmic fractions of untransfected cells were used 
as negative control.  C, Northern blot analysis of total RNA isolated from 5’Src-RFLuc-
transfected (lane 3) and untransfected (lane 4) Huh7 cells.  Lanes 1 and 2 show position 
of monocistronic (5’Src-FLuc) and dicistronic (5’Src-RFluc) RNAs respectively as RNA 
markers.   The 32P-labeled oligonucleotide probe was derived from 3’ end of the FLuc 
ORF.  Overexposure of the film during autoradiography (for more than a week) did not 





(lane 6) and was comparable to that of wild type 5’Src-FLuc RNA.  The predicted 
structure of this mutant c-Src motif (not shown) by M-Fold program showed significant 
similarities in the domains I and II of the wild type structure (Fig. 4.3).  
 
To determine stability of the reporter constructs, we translated 32P-labeled 
uncapped mutant and wild type RNAs in HeLa cell-free lysates as described above.  
Total RNAs from each reaction were isolated by RNeasy column method and the input 
probes were visualized by autoradiography.  As shown in Fig. 4.6C (upper panel), the 
amounts of full-length mutant RNAs recovered (lanes 2-5) were similar or better than 
that of the wild type 5’Src-FLuc (lane 1).  The quantity of 18S rRNA (internal control) in 
each lane had minor variations (lower panel).  This observation suggests that the mutant 
RNAs were although present in the lysates, yet these RNAs were unable to support 
translation of FLuc due to absence of essential elements in the c-Src sequence motif.  The 
different band intensities observed for the RNA probes may likely be due to minor 
differences in stability and/or loss during purification process.  A similar observation was 
also made during transfection of three mutant RNAs (D2, D3 and DC) into Huh7 cells.   
Although full-length mutant RNA probes were purified from the transfected cells (Fig. 
4.6F), only D3 mutant showed efficient synthesis of reporter FLuc (Fig. 4.6E).  These 
results further suggest that a functional IRES that is represented by the c-Src motif in D3 
mutant (Domains I and II, Fig.4.3) was capable of directing translation by cap-
independent mechanism in cells as well as in the cell-free lysates.  Unlike known cellular 





We carried out kinetic analysis of translation promoted by the wild type and 
mutant c-Src motifs in HeLa translation lysates.  The time-course experiment presented 
in Fig. 4.6 D shows that translation of the 5’Src-FLuc RNA exponentially increased with 
time whereas the mutant 5’SrcD2-FLuc was translated inefficiently at all time-points.  
During our investigations (Fig. 4.6D and 4.6E), a minor translation was consistently 
observed for D2 mutant RNA.  It is possible that sequence motifs that form domain I and 
translation site in this RNA might have played a role in the residual translation.  These 
motifs are, however, absent in D1 and DC mutants that are completely incompetent for 
translation initiation.  
 
3.5.  Assembly of 80S initiation complex on the c-Src IRES in HeLa cell-free 
translation lysates is not affected by inhibition of eIF2   
 
 Sucrose density gradient analysis was carried out to study assembly of 80S 
translation initiation complex on the c-Src IRES.   The 32P-labeled uncapped 5’Src-FLuc 
RNA or capped FLuc was incubated for 15 min in HeLa cell-free translation lysates 
containing 1 mM GMP-PNP, a nonhydrolyzable GTP analogue, which causes 
accumulation of 48S complex and inhibition of 80S formation on a capped mRNA 
(Pestova et al 1998, Pestova et al 2008).  The reaction mixtures were analyzed for 
ribosome assembly on the mRNAs by 10%-30% sucrose density gradient centrifugation 
method. The initiation complexes in the gradient fractions were determined by 




single peak (Peak I, solid line with squares) of ribosomal complex containing the input 
RNA probe, 18S and 28S rRNA was obtained for the 5’Src-FLuc RNA (Fig. 4.7B, lane 
4).  The result clearly established assembly of 80S complex on the c-Src 5’NCR motif, 
which was not inhibited by 1 mM GMP-PNP (Fig. 4.7A and 4.7B).  In a similar 
translation reaction, we further reduced GTP and ATP concentrations by omitting the 
10X reaction buffer from the translation mixture.  This omission caused 10-times 
increase in the GMP-PNP to GTP ratio during translation.  Interestingly, 80S assembly 
on the 5’Src-FLuc mRNA probe occurred (Peak I, broken line with squares; Fig. 4.7B, 
lane 5) similar to the standard reaction conditions described above.  On the contrary, 
when a capped FLuc mRNA probe that lacks the c-Src motif was used in a standard 
translation reaction supplemented with 1 mM GMP-PNP, only 48S complex was 
obtained as expected (Peak II, solid line with triangles). This conclusion was based on the 
observation that peak II lacks 28S RNA, showed lower sedimentation than peak I, and 
contains only input RNA probe and 18S rRNA (Fig. 4.7B, lane 7).  In addition, the 48S 
complex assembly was considerably reduced when cap structure was absent in the FLuc 
RNA probe (Peak II, broken line with triangles, Fig 4.7A and Fig. 4.7B, lane 6).   The 
GMP-PNP is known to inhibit GTPase function that is required for the assembly of 80S 
complex on a capped mRNA.   Thus, the observed cap-independent 80S assembly on the 
c-Src IRES is most likely to be independent of eIF2 function. 













Figure 4.6.  Effect of deletion mutations on the c-Src sequence-controlled translation of 
reporter RNAs.   A, The organization of in vitro transcribed uncapped wild type reporter 
RNA (5’Src-RFluc) and the mutants containing various lengths of deletions (D) in the c-
Src sequences are shown; dashed line, extent of deletion.  AUG, initiator codon is 
underlined.  B,  The RNAs were translated for 1.5 hr in HeLa lysates in the presence of 







Figure 4.6 continued. C,  Stability of the reporter RNAs in HeLa translation lysates.  
The 32P-labeled reporter RNAs (~1x106 dpm) were added to a standard HeLa translation 
mixture for 1.5 hr and total RNAs were isolated by Qiagen RNeasy column method.  Half 
of the eluted RNA samples (20 ul) were subjected to formaldehyde-agarose gel 
electrophoresis.  The gel was photographed after ethidium bromide staining for detection 
of ribosomal RNAs (lower panel), dried and autoradiographed (upper panel).  Reporter 
RNAs are as indicated for each lane.  D,  Comparison of the kinetics of translation 
between wild type 5’Src-FLuc and  a deletion  mutant (5’SrcD2-FLuc).  The RNAs were 
translated in a standard HeLa lysates mixture and FLuc activities were assayed with an 













Figure 4.6 continued.  E,  Transfection of uncapped monocistronic c-Src mutant RNAs.  
The Huh7 cells (80% confluent in 60 mm culture plates) were transfected in triplicates 
with uncapped RNAs as indicated and FLuc activities were assayed 3 hrs post 
transfection in the total lysates.  F,  Relative stability of mutant reporter RNAs in the 
transfected cells.  The 32P-labeled mutant RNAs (as indicated) were transfected as above.  
The total RNAs were isolated and the labeled RNAs were detected by agarose gel 
electrophoresis followed by autoradiography of the dried gel (upper panel).  Lower panel, 








  In a similar experiment, the assembly of ribosomal complex on a mutant 
poliovirus 5’NCR containing FLuc (PVD286-605-FLuc) was compared with the 5’Src-
FLuc RNA in the presence of 1 mM GMP-PNP (Figs. 4.7C and 4.7D).  The uncapped 
5’Src-FLuc RNA showed assembly of 80S in a reproducible manner (Peak I, squares 
with solid line; Fig. 4.7D, lane 3).  However, the uncapped PVD286-605-FLuc RNA 
showed a peak at lower sucrose density (Fig. 4.7C, Peak II, triangles with broken line; 
Fig 4.7D, lane 4) and the complexes were spread over a wide range of sucrose density, 
most likely due to varying composition of ribonucleoprotein complexes formed with the 
mutant PV RNA.  
 
The assembly of 80S on the c-Src IRES was further strengthened by our finding 
that purified HeLa 40S ribosomal subunit directly interacts with the c-Src IRES (Fig. 
4.8A).  The purified 40S subunit was mixed with uncapped 32P-labeled IRES fragment of 
the 5’Src-FLuc and bound complex was separated from the free probe by sucrose density 
gradient centrifugation.  Characterization of the peak fractions revealed the presence of 
18S rRNA and the probe in the same peak (inset, lane 1) while the free IRES probe 
showed a peak at lower sucrose density.   A non-specific RNA probe of similar length 
and nucleotide contents (PVD286-605 5’NCR) failed to form 40S-RNA binary complex 
in this assay (Fig. 4.8B and inset lane 2).  These results together provide evidence that the 
c-Src mRNA contains an IRES element that directly interacts with the 40S ribosomal 
subunit and is capable of assembling 80S complex during conditions when eIF-2 function 





3.5. c-Src IRES-mediated translation is enhanced when cap-dependent 
translation is inhibited.   
 
The eIF4E protein is a key translation initiation factor that binds the 5’ cap 
structure of an mRNA and initiates assembly of 48S pre-initiation complex (Sonenberg 
and Hinnebusch 2007).   
          It has been shown that m7GDP inhibits eIF4E function by occupying its cap-
binding site.  Therefore, cap-dependent translation is efficiently inhibited by the m7GDP 
cap analogue (Kentsis et al 2005).  The cap-dependent translation of a FLuc RNA which 
contains 5’cap and 3’polyA tail at the respective ends of the luciferase ORF but lacks an 
IRES (5’Cap-FLuc), was inhibited by m7GDP in a dose-dependent manner in RRL (Fig. 
4.9A).  In contrast, the HCV IRES-controlled translation of a reporter FLuc ORF 
(5’HCV-FLuc) was stimulated until a threshold concentration (10 ug) of m7GDP was 
reached.  Above this concentration, both cap- as well as HCV IRES-dependent 
translations were inhibited.  Interestingly, translation of the 5’SrcD3-FLuc RNA (genetic 
organization shown in Fig. 4.6A) was considerably enhanced in the presence of m7GDP 




















Figure 4.7 Assembly of translation initiation complexes on the c-Src IRES in HeLa cell-
free lysates and analysis by sucrose density gradient centrifugation.   A,  The translation 
mixtures were incubated with 1 mM GMP-PNP on ice-bath for 5 min and in vitro 
transcribed 32P-labeled RNAs: 5’Src-FLuc (squares in solid line) or capped FLuc (lacking 
IRES, triangles in solid line) or uncapped FLuc (triangles in broken line) were added to 
the translation reaction and incubated for 15 min at 30°C.  The complexes formed in the 
absence of exogenous ATP and GTP on the 5’Src-Fluc probe is shown as squares in 
dashed line.  The lysates were separated by 10%-30% sucrose density gradient 
centrifugation and fractions (250 ul) were collected from the bottom of the tube to 
determine RNA contents.  B,  Total RNAs from the peak fractions (Peak I or Peak II) 
were isolated and analyzed by agarose gel electrophoresis. Marker lanes: 1, input 5’Src-
FLuc RNA probe; 2, total RNA extracted from HeLa S10 translation lysate showing 18S 
and 28S rRNAs; 3, 18S rRNA extracted from purified 40S subunit.  The total RNAs 
extracted from Peak I (fractions 5 and 6) for 5’Src-Fluc probe are shown in lanes: 4, 
standard translation reaction shown as squares in solid line (section A), and 5, translation 
reaction deficient in exogenous ATP/GTP (squares in broken line shown in A).  RNAs 






Figure 4.7 continued: C, Comparison of ribosomal complex formed at wild type c-Src 
IRES and a mutant PV 5’NCR used as scrambled IRES in the presence of 1 mM GMP-
PNP.  The 32P-labeled uncapped 5’Src-Fluc (squares in solid line) or 5’PV(D286-605)-
FLuc (scrambled IRES, triangles in dashed line) RNAs were used in sucrose gradient 
centrifugation analysis as described above.  D,   The total RNA isolated and resolved by 
agarose gel electrophoresis is shown.  Lanes 1 and 2, rRNA (as markers) isolated from 
lysates and purified 40S subunit respectively; lanes 3 and 4, RNA isolated from Peak I 










Figure 4.8.  Direct binding of the c-Src IRES with purified HeLa 40S ribosomal subunit.   
A, Purified HeLa 40S subunit was mixed with 32P-labeled RNA representing c-Src nt 1-
383 (solid line) and subjected to sucrose density gradient centrifugation.  A separate 
sample without 40S was run to locate position of the free probe (broken line) during 
sedimentation.  Peak fractions were analyzed for RNA contents (inset).  Inset, lanes: M, 


















Figure 4.8. continued. B,  An experiment similar to that described in section A but 
repeated with a scrambled IRES [5’PV(D286-605)]  as indicated.   Inset: lane M, 18S 










Next, we examined translation of a capped dicistronic RNA (5’Src-RFLuc, Fig. 
4.5A) in RRL in the presence of increasing concentrations of m7GDP.   The wild type c-
Src IRES-controlled translation of FLuc was initially enhanced in the presence of m7GDP 
(5-10 ug) as observed for its monocistronic counterpart, whereas cap-dependent 
translation of the upstream renilla luciferase (RLuc) ORF continued to decline with 
increasing concentrations of m7GDP (Fig. 4.9B).  Although the requirement of inhibitor 
concentration to inhibit overall translation was a little higher than that of the 
monocistronic RNAs, the stimulation pattern of the c-Src IRES in the presence of 
m7GDP was similar for both mono- and dicistronic templates.  During several control 
experiments , we observed that m7GTP cap analogue also causes stimulation of the c-Src 
IRES in HeLa and RRL cell-free translation systems whereas the unmethylated 
nucleotides (GTP or GDP) had no effects within the concentration range used in our 
studies.  These results together with those described above (Figs. 4.4, 4.6 and 4.7) 
established the presence of a functional IRES in the c-Src mRNA that can be activated 
when cap-function is absent or significantly inhibited and/or eIF-2 activity is inadequate 
in the translation system.   
 
We treated Huh7 cells with 1 uM TG for different time-points (0.5 to 6 hrs) and 
monitored the status of eIF2a by Western blot.   We observed a considerable increase in 
the phosphorylation level of eIF2a within 30 min of TG-treatment, which remained 
elevated for 6 hr (Fig. 4.10A, lanes 2-6, upper panel).  The total eIF2a level, on the other 




phosphorylation may be considered as an indicator for TG-induced cellular stress and 
reduction in global cap-dependent translation in the treated Huh7 cells.   In the 
subsequent experiments, Huh7 cells were pre-treated with 1 uM TG for 3 hr before 
transfection with the capped 5’Src-RFLuc or RL-HCV1b RNAs while maintaining 1 uM 
TG.  The RL-HCV1b is similar to the 5’Src-RFLuc except that the translation of FLuc 
ORF in the RNA is driven by an HCV IRES.  The FLuc and RLuc activities were assayed 
in the cytoplasmic fractions 3 hrs post-transfection.  The translation of reporter 
luciferases in untreated transfected cells (control) were considered as 100% and 
compared to that of DMSO- or DMSO-TG- treated cells (Fig. 4.10B).   Both the cap-
dependent and IRES-dependent (HCV or c-Src) translation was not affected by DMSO 
treatment of the cells. In contrast, the cap-dependent translation of RLuc was 
dramatically reduced for both the RNAs due to DMSO-TG treatment of the cells.  In 
these cells, however, the c-Src or HCV IRES-controlled translation of FLuc was 
moderately enhanced.  These results together complement our findings that the c-Src 
level in Huh7 cells is modestly enhanced or maintained to steady level under varying 
cellular stress conditions that are unfavorable for cap-dependent translation.  This effect 
is likely to occur due to increase in the c-Src IRES activities. 
 
4.   Discussion 
 
An overwhelming majority of reports including polysome-profiling data strongly 
advocate for IRES-dependent translation initiation of a subset of cellular mRNAs during 




translation initiation is compromised (Spriggs et al 2008). Unlike known cellular IRESs, 
the c-Src IRES demonstrated here exhibits many unique attributes that are analogous to 
the characteristics of HCV-like IRESs.  To identify an IRES function in viral and cellular 
mRNAs, mono- and di- cistronic RNA-expressing plasmids have been extensively used 
during transfection studies.  This approach, however, has been a subject of criticism due 
to expression via cryptic promoters, and faulty transcription and splicing of the reporter 
constructs (Kozak 2007). To avoid spurious results generated by this method, we have 
used only in vitro transcribed capped and uncapped reporter RNAs for cell-free 
translation assays, transfection studies, and sucrose density gradient analyses.  The 
transcription reactions were digested with DNase I prior to purification and checked by 
agarose gel electrophoresis for the absence of DNA contamination in the final RNA 
preparations.  Furthermore, the reporter RNA transcription is under the control of T7 
promoter and transcription of the RNA from plasmid DNA contamination is not possible 
in any of the system used here.   
 
We also demonstrated that wild type and mutant c-Src motif containing reporter 
RNAs were intact during various translation assays.  These measures permitted us to 
present reliable data for the identification of c-Src IRES.  
 
We established here that the c-Src IRES-controlled translation can be stimulated 
similar to the HCV IRES when eIF4E function is blocked (Fig. 4.9).  The initiation factor 


















Figure 4.9.  Stimulation of the c-Src IRES-controlled mRNA translation when eIF4E 
function is inhibited.  A, Capped RNAs: 5’Src-FLuc (triangle), and FLuc (5’Cap-FLuc, 
circle) or uncapped 5’HCV-FLuc (square) RNAs were translated in triplicate in the 
presence of increasing amounts of m7GDP in RRL for 1 hr, and one-tenth of each 
reaction mixture was assayed for FLuc activity.  Average FLuc activity of three reactions 
is shown for each m7GDP concentration.  The FLuc activity in samples without m7GDP 
was considered as 100% translation and compared with those containing the cap analogue 
(inhibitor).  Similar translation reactions were carried out twice to confirm the results.  B,  
Translation of a capped dual luciferase RNA construct (5’Src-RFLuc) in RRL in the 
presence of increasing amounts of m7GDP as described above.  Relative cap-dependent 
translation of renilla luciferase (RLuc) and c-Src IRES-dependent FLuc synthesis are 
shown.  Each translation mixture was carried out in triplicate.  The results were 
































translation of IRES-containing RNAs is accelerated when eIF4E availability is reduced 
(Svitkin et al 2005).  This is likely attributed to a decrease in eIF4F complex formation 
that may be accompanied by an increased availability of eIF4G/eIF4A or eIF4A RNA 
helicase or other initiation factors.  Based on these observations, we believe that a direct 
binding of m7GDP to eIF-4E in our assay may lead to increased availability of translation 
factors that are required for efficient activities of the HCV or c-Src IRESs.  
 
Our in vitro studies that defined presence of an IRES in the c-Src mRNA were 
further corroborated by the results of transfection of mono- and dicistronic reporter RNAs 
into hepatoma-derived cells and induction of cellular stress in the transfected cells.  
Uncapped reporter RNAs containing nt 1-383 of c-Src mRNA at their 5’ends were 
efficiently translated in two cell-free translation systems (RRL and HeLa lysates) and in 
Huh7 cells.   Our genetic analysis shows that nt 200-383 of the c-Src mRNA, which 
harbors initiator AUG (at nt 351), plays pivotal role in promoting cap-independent 
translation.  An extensive analysis of the secondary and/or possible higher-order 
structures within this region is, however, needed for accurate understanding of its role in 
loading productive initiation complex.   We found that the c-Src IRES promotes assembly 
of stable 80S complexes in the absence of cap structure and in the presence of 1mM 
GMP-PNP.    Under similar conditions, however, only 48S complex can be trapped on a 





Figure 4.10. c-Src IRES-controlled translation is not inhibited during cellular stress. A, 
Phosphorylation of eIF2a  by thapsigargin (TG) treatment.  The cytoplasmic lysates (40 
ug) from Huh7 cells that were treated with 1 uM TG for 0.5, 1, 2, 4 and 6 hrs (lanes 2-6) 
were subjected to Western blot analysis using anti-[Phospho-eIF2α(Ser51)] antibody 
(Cell Signaling, upper panel) and anti-eIF2a antibodies (Sigma, lower panel).  Lane 1, 0 
min treatment.   B,   Huh7 cells in triplicate were treated with DMSO alone or 1 uM 
thapsigargin dissolved in DMSO (DMSO-TG) for 3 hrs followed by transfection with in 
vitro transcribed capped 5’Src-RFLuc RNA (solid black bar) or RL-HCV1b (solid gray 
bar).  The upstream RLuc in RL-HCV1b RNA is translated by cap-dependent mechanism 
whereas HCV IRES mediates downstream FLuc translation.  The cytoplasmic lysates 
were assayed for FLuc (IRES-dependent translation) and RLuc (cap-dependent 
translation) activities 3 hours post-transfection.  The activities of FLuc and RLuc in 
untreated (control) samples were considered as 100% and compared with the solvent 




Furthermore, similar to the HCV-like IRESs, a direct binding of purified HeLa 
40S with the c-Src nt 1-383 was detected in the absence of initiation factors.  These 
evidence together strongly support existence of a physiologically relevant IRES element 
at the 5’ end of c-Src mRNA.  The c-Src IRES appears to be functionally similar to the 
HCV IRES as both IRES elements directly interact with the purified 40S subunit, require 
coding region for their functions, promote eIF2-independent assembly of 80S complex 
(Figs. 4.4, 4.6 and 4.7) (Pestova et al 2008, Reynolds et al 1995, Robert et al 2006), and 
are stimulated when eIF4E or eIF2a function is impaired (Figs. 4.9 and 4.10).  Therefore, 
our studies reported here present several unique attributes of a cellular IRES that have 
been demonstrated only for HCV-like IRESs.  
 
The sucrose gradient analyses further provided insights into the mechanism of 
ribosome assembly on the c-Src IRES.  The nonhydrolyzable GTP analogue, GMP-PNP, 
blocks eIF2-dependent initiation pathway at the 48S complex stage (Pestova et al 1998, 
Pisarev et al 2007).  This effect was clearly evident for the cap-dependent translation 
initiation of the FLuc mRNA in HeLa cell-free lysates in which the 48S complex was 
trapped by 1mM GMP-PNP treatment (Fig. 4.7).  Thus, the GMP-PNP concentration 
used here during translation initiation assembly was sufficient to block 80S assembly by 
cap-dependent initiation mechanism in the translation mixture.  In sharp contrast, 
assembly of 80S complex took place on the c-Src IRES in the presence of GMP-PNP or 
in a reaction mixture containing the analogue but was also deficient in exogenously 




after eIF5-induced GTP hydrolysis and dissociation of eIF2.GDP complex (Terenin et al 
2008).  This step is preceded by ATP-dependent scanning by the 48S complex to locate 
AUG codon (Sonenberg and Hinnebusch 2007).  From the data presented here, c-Src 
IRES appears to evade both of the critical energy-dependent steps that are needed for the 
80S assembly by cap-dependent mechanism.  Because the c-Src IRES directly binds 40S 
subunit (Fig. 4.8) and the structural motifs from flanking regions of the initiator AUG are 
required for efficient function of the c-Src IRES (Fig. 4.6), it is highly likely that the 48S 
complex formed at this element may not require energy-dependent scanning for the 
initiator AUG.  This notion is supported by the genetic analysis of the c-Src IRES.   A 19 
nt-deletion at translation site in 5’Src-D1-FLuc RNA resulted in complete impairment of 
the IRES function in spite of the presence of upstream AUG147 and AUG179.  Recently, 
the HCV IRES was shown to switch from classical eIF2-dependent initiation to eIF2-
independent pathway under cellular stress that favors inactivation of eIF2 due to 
phosphorylation of its a subunit.  This alternative pathway was further shown to require 
only eIF3 and eIF5B (an analogue of bacterial IF2) for Met-tRNAiMet delivery at the P 
site.  Based on these observations, it was proposed that the 80S assembly on the HCV 
IRES is analogous to bacterial-like mode of translation initiation (Terenin et al 2008).   In 
this context, the c-Src IRES appears to follow HCV IRES-like mode of translation 
initiation when the GTPase function of the ternary complex is blocked.  This conclusion 
is further supported by RNA transfection studies in which thapsigargin-led induction of 
cellular stress in Huh7 cells failed to inhibit the c-Src IRES in spite of increased Ser51 





The studies presented here demonstrate significant resistance of the c-Src IRES 
activities to reduced level of ternary complex (TC) and eIF-2a phosphorylation.  In 
contrast to the eIF2-dependent initiation pathway in which the eIF-2 complex delivers 
Met-tRNAi to 40S subunits in a GTP-dependent manner, the eIF2A has been shown to 
deliver the Met-tRNAi to 40S subunits by AUG-dependent and GTP-independent 
mechanism (Robert et al 2006, Zoll et al 2002).  In addition, a number of RNA-binding 
proteins have been shown to stabilize IRES structure and/or promote ribosomal complex 
assembly (Ali and Siddiqui 1997, Wang et al 1995).   A comprehensive analysis is 
needed to ascertain whether these factors contribute to the reduced TC-dependence of the 
c-Src IRES. 
 
 In the cells, stress and serum-deprivation causes inhibition of PI3K/AKT/mTOR 
pathway-dependent phosphorylation of eIF4E-BP.  The unphosphorylated protein forms a 
tight complex with eIF4E and prevents its binding to eIF4G and the cap structure 
(Gingras et al 1999).  Similarly, hypophosphorylation of eIF4E that is controlled by Ras-
MAPK pathway also reduces its cap-binding ability.  Both of these events culminate into 
suppression of global cap-dependent translation.  In addition, phosphorylation of eIF2a 
by cellular kinases (e.g. PKR, PERK, HR1 and GCN2) in response to various cellular 
stress and viral infections leads to reduction in the level of ternary complex (eIF2-GTP-
Met-tRNAiMet) due to inhibition of guanine nucleotide exchange factor (GEF) activity 
(Fernandez et al 2002).   Our investigations revealed that 80S assembly on the c-Src 




the c-Src mRNA can easily escape from tight regulation of both of these translation 
initiation factors, which may ultimately lead to continued c-Src protein synthesis during 
adverse conditions (e.g. ER stress and starvation).  Enhanced c-Src level has been shown 
to correlate with its activated state in hepatocellular carcinoma (Ito et al 2001).  Activated 
c-Src is known to induce phosphorylation of 4E-BP1 via PI3K/mTOR and eIF4E via 
Ras/Raf/ERK pathway, both of which favor cell survival and proliferation (Karni et al 
2005, Vojtechova et al 2008).  Thus, the c-Src IRES controlled translation provides an 
important recovery mechanism from translational blockade during cellular stress.   
 
It has been shown that the cap-dependent translation of c-Src mRNA is regulated 
by elements located in its long 3’NCR through interaction with hnRNP K (Naarmann et 
al 2008).  It would be interesting to investigate if hnRNP K or miRNAs can affect the c-
Src IRES-controlled translation through the 3’NCR interactions.  Both transcripts of the 
c-Src gene (Type-1A and Type-1a, Fig.4.1A) contain conserved sequences that constitute 
most part of the IRES element.  However, the extreme 5’ ends in these mRNAs are 
dissimilar in length and nucleotide composition.  It is not known if these sequences play 
any role in regulating the c-Src translation.    
 
c-Src is an important player in signal transduction pathways that control 
oncogenesis, cell-proliferation and metastasis (Alvarez et al 2006, Bjorge et al 2000, Finn 
2008, Fizazi 2007).  The emerging strategies for treatment of breast, lung, prostate, skin 
and other cancers are focused on the inhibition of c-Src activities (Giaccone and Zucali 




supply of c-Src in the tumor cells.  Many of the small molecules that target c-Src 
activities also inhibit other protein kinases and/or show high degree of cytotoxicity (Ma 
and Adjei 2009).  Adaptation for growth during cellular stress is a hallmark feature of 
many cancer cells and c-Src has been shown to play very important role during this 
process (Yamamoto et al 2006).  Our report presents c-Src IRES as a new therapeutic 
target for treatment of cancer.  Because the c-Src IRES is located downstream of the cap 
structure in the mRNA, interference with the IRES structure and/or function will likely 
result in the inhibition of cap-dependent as well as IRES-dependent c-Src synthesis.  This 
strategy will prevent unabated c-Src supply in the cancer cells, and hence is likely to 
reduce the chances of cancer cell survival. 
 
5.   Chapter Summary 
 
Overexpression and activation of c-Src protein have been linked to the 
development of a wide variety of cancers.  The molecular mechanism(s) of c-Src 
overexpression in cancer cells is not clear.  We report here an internal ribosome entry site 
(IRES) in the c-Src mRNA that is constituted by both 5’ noncoding and coding regions.  
The inhibition of cap-dependent translation by m7GDP in cell-free translation system or 
induction of ER stress in hepatoma-derived cells resulted in stimulation of the c-Src IRES 
activities.  Sucrose density gradient analyses revealed formation of a stable binary 
complex between the c-Src IRES and purified HeLa 40S ribosomal subunit in the 
absence of initiation factors.  We further demonstrate eIF2-independent assembly of 80S 




reminiscent to that of hepatitis C virus-like IRESs and translation initiation in 
prokaryotes.  Transfection studies and genetic analysis revealed that the c-Src IRES 
permitted initiation at the authentic AUG351 which is also used for conventional 
translation initiation of the c-Src mRNA.  Our studies unveiled a novel regulatory 
mechanism of c-Src synthesis mediated by an IRES element, which exhibits enhanced 
activity during cellular stress, and is likely to cause c-Src overexpression during 





















Chapter Five: Summary 
 
Hepatitis C virus (HCV) is a positive strand RNA virus and has been classified as 
a hepacivirus of the family Flaviviridae. More than 180 million people (>4 million in 
USA alone) have already been infected and HCV-related liver diseases are on rising trend 
globally due to addition of 3-4 million new cases per year. The HCV infection causes 
chronic hepatitis (70%-80%) that may lead to the development of cirrhosis, steatosis and 
hepatocellular carcinoma (HCC). In spite of aggressive efforts during last 15 years by 
scientists and pharmaceutical companies, cure for the infection as well as vaccine against 
the virus remained elusive.  The current standard-of-care treatments (e.g. interferon with 
ribavirin for 24-48 weeks) alone or in combination with the HCV-specific drugs (e.g. 
telaprevir and boceprevir) have shown partial success. The HCV-related HCC are 
believed to contain a subpopulation of poorly differentiated cancer stem-like cells 
(CSCs), which exhibit a strong potential to initiate tumor formation and resistance to anti-
neoplastic drugs.  Keeping in view of the above described problems, my thesis work was 
focused on three major specific aims: 1) To investigate if HCV-expressing cells undergo 
phenotypic changes and exhibit enhanced expression of oncogenes (e.g. c-Src) and 
putative cancer stem cell markers, 2) To investigate possible mechanism of the HCV-
induced hepatocarcinogenesis, 3) To develop novel means for targeting marker (s) that 




In these studies, we demonstrate that expression of HCV subgenomic replicon in 
cultured cells results in acquisition of CSCs traits.  These traits include enhanced 
expression of DCAMKL-1, Lgr5, CD133 and c-Myc in conjunction with long-term 
maintenance of pluripotency factors. We also show that HCV replication is severely 
impaired by siRNA-led depletion of the microtubule-associated putative stem cell 
marker, DCAMKL-1. The DCAMKL-1-positive cells isolated by fluorescence activated 
cell-sorting (FACS) form spheroids in matrigel.   We further demonstrate that HCV 
replicon-expressing cells initiate tumors in nude mice. The resulting tumors exhibit 
characteristics of HCCs that are originated from hepatic progenitor-like cells and are 
phenotypically distinct from the tumors initiated by parent cells lacking the replicon.  
This phenotype expresses high-levels of -fetoprotein, cytokeratin-19 and pluripotency 
markers.  HCV-induced activation of -catenin, c-Myc, and c-Src indicates the 
aggressive nature of the tumor. These results collectively suggest that HCV exhibits 
ability to induce reprogramming and/or retrodifferentiation of the host cells. 
  
DCAMKL1 is a putative stem cell/CSC protein that affects ‘dynamic instability’ of 
microtubule filaments (MTFs), a process required for movement of HCV replication 
complexes (RCs), cellular transport and survival.  Our findings that this protein is 
overexpressed in HCV replicon model and DCAMKL-1 antagonist leads to specific 
reduction in the HCV RNA and protein levels are novel. Subsequent studies showed that 
the cholesterol-lowering drug, fluvastatin (FLV, inhibitor of HMG CoA reductase), induce 




normal human hepatocytes. However, pravastatin failed to show such effects under similar 
conditions. The fluvastatin effect on MTFs was accompanied by changes in localization of 
the RCs and DCAMKL1 with the MTFs. DCAMKL1 RNA level was also reduced to a 
considerable extent by the FLV treatment.  
 
   Because overexpression and activation of c-Src protein have been linked to the 
development of a wide variety of cancers including HCC, we investigated molecular 
mechanism(s) of c-Src overexpression in hepatoma cell lines.  The studies revealed a 
novel type of internal ribosome entry site (IRES) in the c-Src mRNA that is constituted 
by both 5’ noncoding and coding regions.  The inhibition of cap-dependent translation by 
m7GDP in cell-free translation system or induction of ER stress in hepatoma-derived cells 
resulted in stimulation of the c-Src IRES activities.  Sucrose density gradient analyses 
revealed formation of a stable binary complex between the c-Src IRES and purified HeLa 
40S ribosomal subunit in the absence of initiation factors.  We further demonstrate eIF2-
independent assembly of 80S initiation complex on the c-Src IRES.  These features of the 
c-Src IRES appear to be reminiscent to that of hepatitis C virus-like IRESs and 
translation initiation in prokaryotes.  Transfection studies and genetic analysis revealed 
that the c-Src IRES permitted initiation at the authentic AUG351 which is also used for 
conventional translation initiation of the c-Src mRNA.  Thus, these results unveiled a 
novel regulatory mechanism of c-Src synthesis mediated by an IRES element, which 
exhibits enhanced activity during cellular stress, and is likely to cause c-Src 




In conclusion, the studies presented here revealed a novel HCV-(DCAMKL-1)-
MTF-CSCs axis that might be responsible for the HCV RNA abundance in the infected 
cells and HCV-induced hepatocarcinogenesis. The putative stem cell marker, DCAMKL-
1, represents a novel cellular target for combating HCV and liver cancer.  We showed 
that its role in the HCV replication could be controlled by a combination of anti-
DCAMKL-1 agent with FDA-approved fluvastatin and/or HCV-specific drugs. The 
concept of a ‘virus-induced stem cell traits’ can also be extrapolated to study diseases 
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Expression and co-expression (indicated with arrows) pattern of cytokeratin 19 (purple) 







DCAMKL1 staining results of the  human liver tissue array.  The arrays were processed 
for immunohositochemical staining.  (A)  Examples of DCAMKL1 intensities in different 
liver diseases.  (B)  Evaluation of DCAMKl1 intensities in different cell populations 






















Translation of capped dicistronic RNA controls in Huh7 cells during transfection assay.  
The Huh7 cultured cells (80% confluency, 50 mm dish) were transfected with 10 ug 
capped RL-HCV1b or a dual luciferase vector lacking an IRES between upstream RLuc 
and downstream FLuc ORFs.  Renilla and firefly luciferase activities were assayed in the 
cytoplasmic fractions as described for Fig. 4.4.  The cap-dependent Rluc and HCV IRES-
















Immunoflorescence detection of FLuc expressed by c-Src IRES-controlled translation of 
5’Src-FLuc RNA in Huh7 cells.  A,  The amino acid sequence encoded by the coding 
region in the c-Src IRES is shown.  HCV IRES containing FLuc (5’HCV-FLuc) lacks 
this sequence.  B, Huh7 cells were transfected with uncapped 5’Src-Fluc or  5’HCV-FLuc  
RNAs.  Indirect immunoflorescence staining for FLuc (green) was carried out with 
monoclonal FLuc antibody 48 hr post-transfection.  Dapi, nuclear staining with bis-
benzimide.  
 
 
 
